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ABSTRACT 
 
Human herpesvirus (HHV)-6A and HHV-6B are two ubiquitous herpesviruses that after primary 
infection can stay latent in the host. The two viruses can reactivate from latency and cause 
secondary complications. Also, diseases like multiple sclerosis and epilepsy have been associated 
with HHV-6A and HHV-6B. However, these associations need to be further examined in order to 
prove relation and to present evidence for how virus-host interactions can play a role in disease 
pathology. In order to investigate the effect of viruses in disease it can, at least in some stages, be 
necessary to perform in vitro experiments. When conducting in vitro experiments, optimal 
conditions are needed in order to obtain accurate and reliable results.  
The first part of the thesis focuses on improvement of in vitro experiential setups. In Study I, we 
sought to develop a correct and robust measurement of virus titers aiming for increased accuracy 
of experiments and better harmonization within the HHV-6A/6B research field. This was done by 
optimizing the classical TCID50 method with a new qPCR readout. This qPCR readout was found to 
be more robust compared to other readouts and this method can be used for HHV-6A titer 
determination. In order to analyze relative gene expression during virus infections, a gene with 
stable expression is needed for normalization. In Study II we searched for a gene with stable 
expression during HHV-6B infection of Molt-3 cells. Comparison of eight different commonly used 
reference genes revealed that PPIA is a gene suitable to use as reference gene when working with 
HHV-6B.  
The second part of the thesis focuses on how HHV-6B affects host cell DNA methylation and if this 
could be one mechanism by which this virus has been associated to epilepsy. Study III reveals, for 
the first time, that HHV-6B induces locus specific host cell DNA hypomethylation close to the 
telomeres. This hypomethylation was observed already 2 days after infection and correlated with 
increased gene expression and integration of the virus genome into the host cell genome. No 
difference in methylation could be observed in epileptic brain tissue which could be due to a 
transient hypomethylation present only in the acute phase of infection or because of under-
powered study design.  
The third and last part of the thesis investigates the association between IgG antibody responses 
against HHV-6A and HHV-6B in MS in order to elucidate if these viruses may play a role in this 
disease. In addition, the influence of environmental factors and host genetics was investigated. 
These studies revealed that there was no difference in response against HHV-6B viral lysate 
between MS cases and controls (Study IV) but that established MS patients and pre-symptomatic 
MS patients had an increased response against the HHV-6A protein IE1A and, to a lesser extent, 
the HHV-6B protein 101K (Study V). The epitope specific IgG responses were highly dependent on 
the host HLA status. Antibody responses can be interpreted in different ways, but the results of 
Study V indicate that HHV-6A and HHV-6B may play a role in MS disease etiology. This virus-host 
interaction in relation to MS needs further investigation.   
  
 
LIST OF SCIENTIFIC PAPERS 
 
I. Development and validation of a Q-PCR based TCID50 method for human 
herpesvirus 6 
Rasmus Gustafsson, Elin Engdahl, Anna Fogdell-Hahn. 
Virol J. 2012;9:311 
 
II. Investigation of reference gene expression during human herpesvirus 6B 
infection indicates peptidylprolyl isomerase A as a stable reference gene and 
TATA box binding protein as a gene up-regulated by this virus 
Elin Engdahl, Nicky Dunn, Anna Fogdell-Hahn. 
J Virol Methods. 2016;227:47-9 
 
III. Human herpesvirus 6B induces hypomethylation on chromosome 17p13.3 
correlating with increased gene expression and virus integration 
Elin Engdahl, Nicky Dunn, Pitt Niehusmann, Sarah Wideman, Peter Wipfler, Albert 
J Becker, Tomas J Ekström, Malin Almgren, Anna Fogdell-Hahn.  
Manuscript 
 
IV. HLA-A*02, gender and tobacco smoking, but not multiple sclerosis, affects the IgG 
antibody response against human herpesvirus 6 
Elin Engdahl, Rasmus Gustafsson, Ryan Ramanujam, Emilie Sundqvist, Tomas 
Olsson, Jan Hillert, Lars Alfredsson, Ingrid Kockum, Anna Fogdell-Hahn. 
Hum Immunol. 2014;75(6):524-30 
 
V. Serological response against an immediate-early 1 protein sequence from HHV-
6A is positively associated with risk for multiple sclerosis 
Elin Engdahl*, Rasmus Gustafsson*, Jesse Huang*, Martin Biström, Izaura Lima 
Bomfim, Mohsen Khademi, Angelika Michel, Julia Butt, Nicole Brenner, Ingileif 
Jonsdottir, Kari Stefansson, Daniel Jons, Maria Hortlund, Lucia Alonso-Magdalena, 
Louis Flamand, Oluf Andersen, Jan Hillert, Lars Alfredsson, Tim Waterboer, Peter 
Sundström#, Tomas Olsson#, Ingrid Kockum#, Anna Fogdell-Hahn# 
* E.E., R.G. and J.H. contributed equally to this work and share first authorship. 
#  P.S., T.O., I.K., A.F-H contributed equally to this work and share senior authorship.  
Manuscript 
  
 
  
 
ADDITIONAL PUBLICATIONS 
 
I. Human herpesvirus 6A partially suppresses functional properties of DC 
without viral replication  
Rasmus Gustafsson, Elin Engdahl, Oscar Hammarfjord, Sanjaya Adikari, 
Magda Lourda, Jonas Klingström, Mattias Svensson, Anna Fogdell-Hahn.  
PLoS One. 2013;8(3):e58122 
 
II. Anti-interferon beta antibody titers strongly correlate between two 
bioassays and in vivo biomarker expression, and indicates that a titer of 
150 TRU/mL is a biologically functional cut-point  
Christina Hermanrud, Malin Lundkvist Ryner, Elin Engdahl, Anna Fogdell-
Hahn.  
J Interferon Cytokine Res. 2014;34(7):498-504  
 
III. First therapeutic use of Artesunate in treatment of human herpesvirus 6B 
myocarditis in a child  
Nina Hakacova, Karin Klingel, Reinhard Kandolf, Elin Engdahl, Anna Fogdell-
Hahn, Thomas Higgins.  
J Clin Virol. 2013;57(2):157-60 
 
IV. Characterization of anti-natalizumab antibodies in multiple sclerosis 
patients  
Malin Lundkvist*, Elin Engdahl*, Carolina Holmén, Robert Movérare, Tomas 
Olsson, Jan Hillert, Anna Fogdell-Hahn.  
* M.L. and E.E. contributed equally to this work and share first authorship. 
Mult Scler. 2013;19(6):757-64  
 
V. Fatal neuroinflammation in a case of multiple sclerosis with anti-
natalizumab antibodies  
Anders Svenningsson, Anna M Dring, Anna Fogdell-Hahn, Iwan Jones, Elin 
Engdahl, Malin Lundkvist, Thomas Brännström, Jonathan D Gilthorpe.  
Neurology. 2013;80(10):965-7. 
 
VI. Prevalence of anti-drug antibodies against interferon beta has decreased 
since routine analysis of neutralizing antibodies became clinical practice 
Roger Jungedal, Malin Lundkvist, Elin Engdahl, Ryan Ramanujam, Helga 
Westerlind, Ajith Sominanda, Jan Hillert, Anna Fogdell-Hahn.  
Mult Scler. 2012;18(12):1775-81 
 
  
  
 
CONTENTS 
1 Introduction ..................................................................................................................... 1 
1.1 Human herpesvirus 6A and 6B.............................................................................. 1 
1.1.1 Basic biology .............................................................................................. 2 
1.1.2 Prevalence studies .................................................................................... 6 
1.1.3 Latency and integration ............................................................................ 7 
1.2 Eliciting an Anti-viral B cell response .................................................................... 8 
1.2.1 Functions of antibodies in anti-viral defense ......................................... 10 
1.2.2 Role of HLA / MHC in anti-viral defense ................................................. 10 
1.3 HHV-6A and HHV-6B Association to diseases .................................................... 11 
1.3.1 Multiple sclerosis (MS) ............................................................................ 11 
1.3.2 Epilepsy .................................................................................................... 13 
1.4 Epigenetics ........................................................................................................... 14 
1.4.1 DNA methylation ..................................................................................... 14 
1.4.2 DNA methylation during virus infection ................................................. 15 
1.5 Genetic association to infection ......................................................................... 16 
1.5.1 Genome Wide Association Studies (GWAS) ........................................... 16 
2 Aims ............................................................................................................................... 18 
3 Material and methods ................................................................................................... 19 
3.1 Study I .................................................................................................................. 19 
3.1.1 Study design ............................................................................................ 19 
3.1.2 Cell culture and HHV-6A propagation .................................................... 20 
3.1.3 TCID50 method with different readouts ................................................. 20 
3.1.4 Other titer determinations ..................................................................... 22 
3.2 Study II-III ............................................................................................................. 22 
3.2.1 In vitro experiments (Study II – III) ......................................................... 22 
3.2.2 In vivo material (Study III) ....................................................................... 23 
3.2.3 Measuring DNA methylation (Study III) ................................................. 23 
3.2.4 Measuring gene expression (Study II – III) ............................................. 25 
3.2.5 Investigation of virus integration (Study III) ........................................... 27 
3.3 Study IV-V ............................................................................................................ 27 
3.3.1 Study participants ................................................................................... 27 
3.3.2 Generating data ...................................................................................... 28 
3.3.3 Analysis of data ....................................................................................... 30 
4 Results and discussion ................................................................................................... 33 
4.1 Study I .................................................................................................................. 33 
4.1.1 Reflections ............................................................................................... 34 
4.2 Study II ................................................................................................................. 35 
4.3 Study III ................................................................................................................ 36 
  
 
4.4 Study IV and V ...................................................................................................... 39 
4.4.1 Association to MS .................................................................................... 40 
4.4.2 How to interpret antibody data? ............................................................ 42 
4.4.3 Associations to gender and age .............................................................. 45 
4.4.4 Genetic associations to anti-HHV-6A/6B epitope specific IgG 
responses ................................................................................................. 45 
4.4.5 Future perspectives in relation to Study V ............................................. 48 
4.4.6 Incorporation hypothesis ........................................................................ 49 
5 Thesis Summary ............................................................................................................. 51 
6 Acknowledgements ....................................................................................................... 52 
7 References ..................................................................................................................... 54 
 
  
  
 
LIST OF ABBREVIATIONS 
 
5caC 5-carboxycytosine  
5fC 5-formylcytosine  
5hmC 5-hydroxymethylcytosine  
5mC 5-methylcytosine  
ACTB β-actin  
APC antigen presenting cell 
BCR B cell receptor  
CI Confidence interval 
CNS central nervous system  
CTL cytotoxic T lymphocyte 
CPE cytopathic effect 
CV coefficient of variation 
DC dendritic cell 
DNMT DNA methyltransferase 
dpi days post infection  
DR direct repeats  
EBNA-1 EBV nuclear antigen 1  
EBV Epstein-Barr virus  
FACS flow cytometry  
FBS fetal bovine serum  
FDR false discovery rate  
FFWO fusion from without  
GST glutathione s-transferase  
GWAS genome wide association study  
HBLV human B-lymphotropic virus  
HCMV human cytomegalovirus  
HHV-6 human herpesvirus 6  
HHV-6A human herpesvirus 6A  
HHV6A/6B HHV-6A and/or HHV-6B, viral species not determined 
HHV-6B human herpesvirus 6B  
HLA human leukocyte antigen  
ici inherited chromosomally integrated  
 
  
 
IE1 Immediate-early 1 protein 
IFA immunofluorescent assay 
Inf U Infectious Units  
LD linkage disequilibrium  
LILRB2 leukocyte immunoglobulin like receptor B2  
MAF minor allele frequency 
MFI median fluorescence intensity  
MHC major histocompatibility complex 
MOI multiplicity of infections  
MS multiple sclerosis  
MTLE mesial temporal lobe epilepsy  
OD optical density  
OR odds ratio 
ORF open reading frames 
PEST penicillin and streptomycin mixture  
PPIA peptidylprolyl isomerase A  
PPMS primary progressive MS 
qPCR real time quantitative PCR  
RPL13 ribosomal protein L13  
RRMS relapsing remitting MS 
SD standard deviation  
SNP single nucleotide polymorphism 
SPMS secondary progressive MS  
TBP TATA-box binding protein 
TCID50 50% Tissue culture Infective Dose  
TCR T cell receptor  
TET ten-eleven translocation  
Th2 T helper cell type 2 
TRS telomeric repeat sequences  
TSA Trichostatin A 
 
  
  
  

 1 
 
1 INTRODUCTION 
1.1 HUMAN HERPESVIRUS 6A AND 6B 
In 1986, a new virus was isolated from patients with lymphoproliferative disorders and AIDS. 
This new virus was given the name human B-lymphotropic virus (HBLV) [1]. However, based 
on similarities to several herpesviruses it was soon renamed to human herpesvirus 6 (HHV-
6) [2]. In the following years, HHV-6 was isolated by several other research groups and it 
became gradually apparent that the different isolated HHV-6 strains could be divided into 
two groups. As the two groups differed in their molecular and biological properties, in 1991 
it was proposed that the virus species HHV-6 should be divided into group A and group B 
[3]. Almost 20 years later, after many more publications highlighting the differences 
between group A and B, HHV-6 was officially replaced by the two distinct virus species HHV-
6A and HHV-6B in the genus Roseolovirus, subfamily Betaherpesvirinae, family 
Herpesviridae [4] (Figure 1).  
                      
Family: Herpesviridae                 
  Subfamily: Alphaherpesvirinae             
    Genus: Simplexvirus             
      Species: Human herpesvirus 1; herpes simplex virus type 1 (HSV-1)   
      Species: Human herpesvirus 2; herpes simplex virus type 2 (HSV-2)   
    Genus: Varicellovirus             
      Species: Human herpesvirus 3; varizella zoster virus (VZV)     
  Subfamily: Betaherpesvirinae             
    Genus: Roseolovirus             
      Species: Human herpesvirus 6A (HHV-6A)       
      Species: Human herpesvirus 6B (HHV-6B)       
      Species: Human herpesvirus 7 (HHV-7)         
    Genus: Cytomegalovirus             
      Species: Human herpesvirus 5; human cytomegalovirus (HCMV)   
  Subfamily: Gammaherpesvirinae             
    Genus: Lymphocryptovirus             
      Species: Human herpesvirus 4; Epstein-Barr virus (EBV)     
    Genus: Rhadinovirus             
      Species: Human herpesvirus 8; Kaposi's sarcoma-associated herpesvirus (KSHV) 
                      
 
Figure 1: Classification of the human herpesviruses, adapted from the International Committee on 
Taxonomy of Viruses (ICTV) homepage: http://www.ictvonline.org 
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The primary infection caused by HHV-6A is not clear but HHV-6B was identified as the causal 
agent of exanthema subitum (“tredagarsfeber” in Swedish) already in 1988 [5]. Since then, 
many studies have investigated the primary infection of HHV-6B and confirmed the 
association between HHV-6B infection and acute febrile illnesses with symptoms such as high 
fever, rashes and febrile seizures in children [6-8]. Less is known about the epidemiology of 
HHV-6A. Most individuals have mounted an IgG response against HHV-6A/6B (viral species 
not determined) before the age of two [9-11], indicating childhood infection with HHV-6A 
and/or HHV-6B in the vast majority of the population. 
An additional dimension of herpesvirus infections is that all herpesviruses have the ability to 
achieve latency in the host [12]. Reactivation of both HHV-6A and HHV-6B might result in 
potentially serious secondary complications, particularly in immunocompromised patients. 
For example, HHV-6B reactivation is common in immunocompromised transplant recipients 
and can lead to encephalitis and other complications in some individuals (reviewed in [13]).  
1.1.1 Basic biology 
1.1.1.1 Cell tropism 
Viruses can enter a target cell by binding of viral glycoproteins to a cellular receptor, after 
which receptor-mediated endocytosis occurs [14]. One receptor for HHV-6A and HHV-6B is 
CD46 [15], a cell surface complement inhibitory protein expressed on all nucleated cells. 
However, it has been discussed that the two viruses interact with CD46 differently [16-18]. 
A more recently discovered receptor is CD134 (also called OX40), a receptor that specifically 
interacts with a HHV-6B glycoprotein complex [19]. OX40 is a member of the TNF receptor 
superfamily expressed on activated T cells that upon binding to its ligand OX40L induce co-
stimulatory effects in the T cells [20]. The time between receptor-mediated virus entry into 
umbilical cord blood lymphocytes and release of new virions is approximately five days [21]. 
Even though both HHV-6A and HHV-6B primarily replicate in CD4+ T cells, the two viruses 
grow optimally in different T cell lines highlighting a difference in their biology [22]. Both HHV-
6A and HHV-6B can replicate in the T cell line SupT1, but HHV-6A grow optimally in HSB-2 cells 
and HHV-6B in Molt-3 and MT4 cells [22]. However, other cell types besides T cells can be 
infected. The two viruses are considered neurotropic as their DNA can be found in human 
brain tissue in vivo [23-26] and because of their ability to infect neuronal cells in vitro. For 
example, human glial precursor cells can be infected by both viruses [27], while only HHV-6A 
can establish a productive infection in astrocytes [28, 29] and oligodendrocytes [30]. 
A hallmark of HHV-6A and HHV-6B infection is their cytopathic effect (CPE) on their host cells. 
Infected cells become enlarged, which can be visualized in a phase contrast microscope (as in 
Study I).  As seen in Figure 2, the infected cells become vacualized though the mechanism 
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behind this is not well studied. In addition, both HHV-6A [18, 31] and HHV-6B [31] can induce 
cell-to-cell fusion, resulting in large multi-nucleated syncytia. This virus-induced cell fusion is 
called fusion from without (FFWO) and does not require viral protein synthesis but is 
dependent on viral glycoproteins in the virus envelope and CD46 on the cell surface. 
 
 
Figure 2: Electron microscopy picture of HHV-6A (GS strain) infected HSB-2 T cells. Both intra- and 
extracellular viral particles are visible as black round dots. Photo E. Engdahl. 
1.1.1.2 Virion structure 
Herpesviruses contain large linear double-stranded DNA genomes which are packed within 
icosahedral capsids. These nucleocapsids (i.e. the genome and capsid) are surrounded by a 
protein compartment called the tegument. Tegument proteins are essential in several 
aspects of the viral life cycle, such as for initiation of viral genome replication and 
modulation of host cell immune responses. A viral envelope, formed of a lipid bilayer 
membrane containing glycoproteins, surrounds the tegument compartment. This envelope 
is obtained from the host cell’s plasma membrane or cellular organelles during the budding 
process (herpesvirus structure reviewed in [32, 33], and can be visualized in Figure 3).  
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Enveloped viruses, like herpesviruses, incorporate not only viral glycoproteins but also host 
cell proteins and lipids in their envelope [34, 35]. Viral particles will therefore contain the 
same sort of proteins/lipids that were present in the specific cell type that generated the viral 
particle. Several different viruses evade complement lysis by incorporating host complement 
regulatory proteins like CD46, CD55 and CD59 into their envelope [36-38]. Hammarstedt et 
al. [39] detected CD46 in HHV-6A virions and we have visualized CD46 with immunogold 
staining on virus envelopes (Figure 3). 
 
 
Figure 3: HHV-6A extracellular virions. The viral particles (HHV-6A GS strain) are on the border of an 
HSB-2 cell, being released to the extracellular space. The black dots are immunogold staining of CD46 
(grey arrow head). Nucleocapsid, tegument and envelope indicated with arrows. Photo E. Engdahl. 
1.1.1.3 Genes 
HHV-6A and HHV-6B share approximately 90% of their overall nucleotide sequence [40, 41] 
and both consist of a long unique region (U) flanked by left and right direct repeats (DR) 
(Figure 4). The DR segments contain open reading frames (ORFs, i.e. a part of the genetic code 
which has the potential to be transcribed and translated into a protein) and two distinct 
arrays of telomeric repeat sequences (TRS). Each DR segment contains two different TRS 
regions. At the right end of the DR segments are the “perfect TRS” composed of tandem 
repeats of the hexamere TAACCC, and at the left end of the DR is the “imperfect TRS” 
composed of the same TAACCC hexameres but interrupted by other hexamers [41-43]. The 
number of TAACCC repeats is highly variable between, but stable within, clinical isolates 
Tegument 
Envelope 
Nucleocapsid 
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and different laboratory strains [44]. As the name TRS implies, the complementary hexamere 
is present in arrays in human telomeric DNA.  
 
Figure 4. Schematic overview of the HHV-6A or HHV-6B genome. Perfect TRS = a perfect tandem 
array of human telomeric repeat sequences (TRS), Imperfect TRS = An array of TRS but not in perfect 
tandem array, U = long unique region, DRL = Direct repeats at the left side of U, DRR = Direct repeats 
at the right side of U. Note that the picture is not in correct scale. 
 
The vast majority of genes are located in the U region. Similar to all herpesviruses, gene 
transcription follows a temporal regulation with immediate early (IE), early (E) and late genes 
(L) being expressed [45, 46]. While some parts of the genome are highly conserved between 
all herpesviruses, other parts are much more species-specific [40, 41].  
The HHV-6A and HHV-6B genome contains 39 genes conserved among all mammalian 
herpesviruses, divided in seven “Herpesvirus core gene blocks”, encoding for example 
structural proteins and enzymes required for DNA replication. One core gene is U66, coding 
for a protein involved in DNA packaging. This spliced protein has a 99.5% amino acid identity 
between HHV-6A and HHV-6B [41].  
The most divergent part of the genome is the IE-A locus [40, 41]. One protein coded in this 
locus, in the ORF U90-U89, is the immediate-early 1 (IE1). As with all IE genes, transcription 
of IE1 occurs within a few hours after virus entry into the cell, and the transcription is 
independent of prior protein synthesis [45, 47]. The IE1 protein has a 62% amino acid identity 
between the HHV-6A (IE1A) and HHV-6B (IE1B) [47, 48] and is therefore one of the most 
divergent proteins between the viruses. Not surprisingly, the proteins not only differ in 
protein sequence but also in protein function. For example, IE1A is a stronger transactivator 
of heterologous promoters compared to IE1B [47, 49], indicating a difference in the two 
proteins’ ability to regulate transcription of host cell genes. On the other hand, IE1B plays a 
role in silencing of IFN-stimulated genes making HHV-6B, but not HHV-6A, resistant to the 
antiviral actions of IFN-α/β [50]. Another gene with high divergence between HHV-6A and 
HHV-6B is the late gene U11 that codes for p100 in HHV-6A and 101K in HHV-6B, two 
tegument proteins with 81% amino acid identity [51]. These structural proteins are essential 
for virus growth and propagation [52] and 101K has been demonstrated to be a highly 
immunoreactive protein that is the dominant antigen recognized by HHV-6A/6B IgG [53].  
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1.1.2 Prevalence studies 
1.1.2.1 DNA studies  
To investigate the prevalence of HHV-6A and HHV-6B one requires the ability to distinguish 
between the two viruses. This can at the moment only be done with PCR performed with 
primers specific for either species. Unfortunately, in the past most research groups have used 
PCR primers that amplify both HHV-6A and HHV-6B DNA (i.e. cannot distinguish the two 
viruses from each other), and therefore these studies cannot be used for determination of 
virus-specific prevalence. 
One question that arises is where to look for the virus DNA, which of course depends on the 
aim of the study performed. If the aim is to investigate the frequency of infected individuals, 
it is important to analyze tissue where the virus is latent, otherwise infected individuals will 
be reported as false negative. In addition, the study population should be drawn from the 
general population.  
Most studies that have investigated HHV-6A and HHV-6B prevalence with PCR on DNA from 
blood and saliva have reported a predominance of HHV-6B [54-57]. For example, HHV-6B 
prevalence has been reported to be 38-60% in PBMC samples and 67-83% in saliva samples 
in healthy adults, while HHV-6A DNA was rarely detected in these tissues sites [55-57]. 
Although blood and saliva are easily accessible, these sites might not be optimal for 
investigation of HHV-6A prevalence since this virus is rarely detected in these compartments. 
Interestingly, the lungs seem to be one important latency site for both HHV-6A and HHV-6B. 
When looking for HHV-6 DNA in lung tissue of adult immunocompetent control individuals, 
100% (14/14) were positive [58]. In a follow up study by the same group, including transplant 
patients and different controls, they detected HHV-6B DNA in 94% and HHV-6A DNA in 71% 
of the investigated lung tissue [59]. This indicates that the lung might be a good site for 
investigation of one individual’s infection status, however, it is not a suitable tissue to use for 
prevalence studies as sampling is problematic. Also, the presence of DNA in tissue exposed to 
the environment does not necessarily mean infection but could be due to for example 
degraded virus DNA in immune cells. 
1.1.2.2 Antibody studies 
Both studies performed by us (Study IV) and others [9, 11, 60-63] have detected IgG 
antibodies against HHV-6A/6B in >75% of the general population. The problem with antibody 
assays used, at least until now, is that they have not been able to distinguish between 
antibodies against HHV-6A and HHV-6B. This makes it hard to use published antibody data in 
order to study the pathology/biology of the two viral species.   
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Antibodies, in contrast to DNA, have the advantage that a serum sample can be used to tell if 
the host has been infected, regardless of infection site in the body. This is of great 
convenience when investigating HHV-6A as this virus rarely detected in saliva or PBMC. In 
addition, when investigating the role of viruses in the brain, measurement of antibodies in 
cerebrospinal fluid (CSF) can reveal intrathecal antibody production allowing an insight to the 
events inside the blood brain barrier.  
There is a need for an assay that can distinguish between antibodies against HHV-6A and HHV-
6B in order to study virus specific disease associations. There have been attempts to address 
this need of a new method. Higashimoto et al. [55] developed an immunoblotting assay with 
the aim to discriminate between antibodies against 101K, encoded by the HHV-6B gene U11, 
and p100 by the corresponding gene in HHV-6A. However, this method could not assure 
absence of cross-reactivity against the proteins. Another group used in vitro HHV-6A or HHV-
6B infected cells measuring all bound human antibodies with immunofluorescent assay (IFA) 
[64]. This cannot be regarded as a strict virus specific measurement as many of the expressed 
proteins are similar between the two virus species. As both the immunoblot assay and the IFA 
assay are laborious and cannot assure species specificity, a high throughput method with the 
ability to distinguish between the serological response against HHV-6A and HHV-6B still needs 
to be developed. This was the aim of Study V. 
1.1.3 Latency and integration 
Even though the different members of the Herpesviridae family have different cell tropisms, 
mechanisms and associated pathologies, all herpesviruses have two distinct stages in their 
life cycle: lytic replication and latency. The mechanism through which latency is achieved 
varies with the different viruses. Both HHV-6A and HHV-6B can achieve latency by integrating 
its genome into the telomeric regions of host cell chromosomes [65, 66], already during lytic 
infection [65]. The mechanism behind this integration into host cell genome is not fully 
understood. However, there are clues.  
As mentioned in section 1.1.1.3, the HHV-6A and HHV-6B genomes contain arrays of 
telomeric repeats (TMRs) within the DR regions. Deletion of these TMRs severely reduces the 
integration of HHV-6A into host cell chromosomes. When comparing deletion of either the 
perfect or imperfect TMR, it was discovered that the perfect TMR is most important for HHV-
6A integration [67]. Taken together, this study by Wallaschek and colleagues [67] indicates a 
central role for the TMRs in HHV-6A integration. As HHV-6A and HHV-6B have similar TMRs, 
it is highly plausible that this also applies for HHV-6B.  
A protein suggested to play an important role in HHV-6A and HHV-6B latency is the U94 [68], 
a protein expressed during IE conditions [45, 46]. This protein is highly conserved between 
the two viruses (96.5% nucleotide sequence identity [41]), but with no orthologue in the 
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other human herpesviruses. Nevertheless, U94 has an overall amino acid identity of 24% with 
the adeno-associated virus type-2 (AAV-2) Rep68 integrase [69, 70]. Interestingly, U94 
possesses all functions required for HHV-6A/6B chromosomal integration: it can bind 
telomeric DNA sequences, hydrolyze ATP and function as both helicase and exonuclease [70]. 
Even though the properties of this protein seem to be of importance in the integration 
process, recent findings revealed that HHV-6A integration takes place even in absence of U94 
[71].  
Another clue to understanding the integration process is that the histone deacetylase 
inhibitor Trichostatin A (TSA) could reactivate HHV-6A from latent integration [65], indicating 
epigenetic control of HHV-6A latency. 
The HHV-6A and HHV-6B integration is not random but takes place at specific sites. One such 
site repeatedly described as a chromosomal integration site for both HHV-6A and HHV-6B is 
the telomere/subtelomere region at 17p [65, 72-75]. Why this location is more suitable for 
integration compared to other sites is not known. However, sequencing of HHV-6A 
integration sites revealed that the integration site at 17p contains TMRs distinct from 
integration sites at other chromosomes [76], possibly facilitating homologous recombination 
with virus TMRs. 
1.1.3.1 ici-HHV-6.  
If virus integration takes place in germ cells, there is a 50% probability that the offspring will 
have this viral genome integrated in every cell of the body. This condition is called inherited 
chromosomally integrated HHV-6A/6B (ici-HHV-6A/6B) and has been detected in 
approximately 1% of the human population (reviewed in [77, 78]). As the viral load in a blood 
sample will be very high, misdiagnosis of active HHV-6A or 6B infection can be a problem. 
Other clinical implications are still being explored, but it has been reported that reactivation 
of these integrated viruses can occur [65, 75] and that virus RNA and proteins are occasionally 
expressed in PBMC from individuals with ici-HHV-6A and ici-HHV-6B [79]. Also, ici-HHV-6A and 
ici-HHV-6B are associated to different disease groups [75].  
1.2 ELICITING AN ANTI-VIRAL B CELL RESPONSE    
B cells are generated in the bone marrow throughout life, each new B cell equipped with a 
unique B cell receptor (BCR). The BCR is a membrane bound IgM or IgD antibody, and as the 
B cell only has one specificity the later secreted antibodies will be specific for the same 
epitope as the BCR. Approximately 50% of the B cells in adults are naive B cells circulating 
between lymphoid organs. The life span of a naïve B cell is a few weeks. However, if a naïve B 
cell find an extracellular antigen which it has specificity for, the BCR will bind the antigen 
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starting a cascade of events in the B cell. Most evident, the BCR-antigen complex is 
internalized, pre-processed and antigen-derived peptides are presented on the MHC class II 
molecules. Binding of antigen also activates B cells and they start to migrate to the T cell zone 
of the lymph node where they can meet T helper cells (Reviewed in [80, 81]; Figure 5).  
 
Figure 5: Simplified illustration of B cell activation. When a naïve B cell bind its antigen, it will induce 
internalization of BCR-Ag complex, B cell activation and presentation of antigen-derived peptides on 
MHC class II. Increased expression of cytokine receptors also makes the B cell migrate to the T cell 
zone of the lymph node. There it can meet a Th2 cell already activated by an activated APC. The 
interaction between MHC class II on the B cell and the TCR on the T cell, with addition of co-stimulatory 
signals, will induce formation of germinal centers where B cell proliferation starts. Here, the antibody 
affinity increases through affinity maturation, i.e. somatic mutations in the Ig genes followed by 
selective survival of B cells producing high affinity antibodies, and the antibody isotype can be changed 
from e.g. IgM to IgG through isotype switching. B cells differentiate into memory or antibody secreting 
cells and leave the lymph node. BCR = B cell receptor, Ag = antigen, APC= Antigen presenting cell, i.e. 
dendritic cell, TCR = T cell receptor, Th2 = CD4+ T helper cell type 2.  
 
 
In order to become a high affinity antibody-secreting cell, binding between MHC class II on 
the B cell and the T cell receptor (TCR) on a T helper cell needs to occur. With the addition of 
co-stimulatory signals and cytokines this binding will induce antibody affinity maturation, 
isotype switching, B cell proliferation and differentiation into memory B cells and plasma-
blasts/plasma cells. Memory B cells can survive for decades and when re-activated they 
proliferate and either differentiate into plasma cells or re-enter germinal center where they 
interact with follicular T helper cells and new rounds off affinity maturation and class 
switching can occur (reviewed in [80]). Plasma cells are terminally differentiated B cells that 
can produce and secrete large amount of antibodies. There are both short lived and long lived 
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plasma cells. Long lived plasma cells reside in the bone marrow where they receive growth 
factors and sufficient support to produce antibodies for years (reviewed in [82, 83]).  
1.2.1 Functions of antibodies in anti-viral defense 
The first antibody isotype produced is IgM, but as B cells undergo class-switch recombination 
they can produce IgG and other classes of antibodies as well. There are different effector 
functions of the different antibody isotypes. The main effector function of IgM antibodies is 
activation of the complement system. Antibodies of the IgG isotype can be divided in to IgG1, 
IgG2, IgG3 and IgG4 and they differ in their ability to interact with the complement system 
and the Fc-receptors. The most common antibody subclass in the human blood is IgG1. One 
major function of all IgG isotypes in anti-viral response is their ability to neutralize virions, 
introducing a steric hinder so that the virus particles cannot bind their receptors, hence 
limiting the spread into other cells. Also, IgG antibodies can opsonize virions and induce Fc-
mediated phagocytosis of the viruses. As the IgM isotype, IgG1 and IgG3 antibodies also 
activate the complement system which can lead to phagocytosis or lysis of viruses and to 
inflammation (reviewed in [81, 84]). However, viruses have evolved strategies to overcome 
complement-mediated destruction (see section 1.1.1.2) and thus avoid some of the  antibody-
mediated anti-viral functions of the immune system.   
1.2.2 Role of HLA / MHC in anti-viral defense 
As seen in Figure 5, MHC class II peptide presentation is needed in different activation steps 
in order to elicit an antibody response. First, it is essential in the interaction between antigen 
presenting cells and naïve CD4+ T cells for their activation into T helper (Th) cells, e.g. with the 
Th2 profile. Secondly, the MHC class II presentation is needed for Th2 activation of B cells to 
proliferate and differentiate into memory B cells and antibody producing plasma cells. In 
addition, MHC class I molecules, expressed on both immune and non-immune cells, 
constantly present peptides derived from within the cell. If the MHC class I presents for 
example viral peptides, the infected cells can be recognized and killed by activated CD8+ T 
cells (i.e. cytotoxic T lymphocytes: CTLs). 
In humans, MHC molecules are encoded by human leukocyte antigen (HLA) genes. Classical 
MHC class I molecules are encoded by the HLA-A, -B and –C locus, while MHC class II 
molecules are encoded by HLA-DR, -DP, and –DQ. Therefore, all individuals will express at 
least three different MHC class I molecules and at least three different MHC class II molecules 
on the cell surfaces. The genetic variation within the MHC region is extremely polymorphic: 
for most of the HLA genes there are very many different alleles, i.e. variants of the genetic 
locus. All HLA-alleles are nowadays named in a certain, very structured way with two-digit 
numbers separated by colons [85]. Most individuals are HLA heterozygous (i.e. different 
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alleles on the two copies of chromosome 6) and as there is expression of both alleles the 
ability to bind different antigens increases even further. Taken together, the HLA molecules 
in one individual should be able to present several antigens from a viral pathogen, making it 
impossible for the infection to go undetected by the immune system. The extensive HLA 
polymorphism in the population ensures that a virus will be detected differently by different 
individuals and thus limit the success of virus escape mutants in a population. The association 
between different HLA alleles and the ability of MS patients and healthy controls to mount 
IgG responses against different HHV-6A and -6B epitopes was investigated in Study V.     
1.3 HHV-6A AND HHV-6B ASSOCIATION TO DISEASES 
1.3.1 Multiple sclerosis (MS) 
Multiple sclerosis is a chronic, inflammatory, demyelinating disease of the central nervous 
system (CNS) with autoimmune features. The average age at onset is 30 years and as with 
many autoimmune diseases, women are overrepresented. The disease is characterized by 
demyelinated areas in the brain and/or spinal cord. In a healthy brain, neuronal axons are 
wrapped with myelin sheaths produced and maintained by oligodendrocytes. Compact 
myelin segments separated by unmyelinated nodes of Ranvier are needed for correct nerve 
signaling. The demyelinated areas in MS are called plaques or lesions. These lesions are 
caused by immune cell infiltration into the brain that induces inflammation, demyelination, 
gliosis and axonal damage (reviewed in [86, 87]).  
Multiple sclerosis is a heterogeneous disease with different disease courses, neurological 
symptoms and progression rates. The most common form of the disease is relapsing-
remitting MS (RRMS) affecting approximately 80-85% of patients. During relapse, CNS 
inflammation and demyelination occur and neurological symptoms arise, but between 
relapses re-myelination and complete remission can occur. As time goes by, the improvement 
between relapses disappears and disability accumulates and eventually approximately 80% 
of RRMS patients convert into secondary progressive MS (SPMS). This phase is less 
inflammatory but instead axonal loss and decreased brain volume is characteristic and during 
this phase there is a constant disease progression (reviewed in [86, 87]) (Figure 6). 
Despite many years of intense research trying to find a cause to this complex disease, the 
main conclusion is that the disease is multifactorial and that there is not one specific causative 
agent. Both genetic and environmental factors are considered to contribute to disease 
susceptibility. Genetic factors influencing MS susceptibility are primarily immune genes [88] 
with human leukocyte antigen (HLA)-DRB1*15 being the strongest risk allele [89, 90] and HLA-
A*02 being a protective allele [89, 91]. Environmental risk factors include smoking [92], low 
vitamin D levels (reviewed in [93]) and infections (reviewed in [94]).  
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Figure 6: Clinical course of MS. The top row (green) shows the clinical symptom of the disease with a 
relapsing-remitting onset later converting to a secondary progressive course. In early stages of MS, 
the inflammation is more profound but as the disease progresses, the brain volume decreases as the 
axons are destroyed (bottom row). Reprinted from Lancet, 2002, 359(9313):1221-31 [86] with 
permission from Elsevier. 
 
 
Epstein-Barr virus is one of the most studied viruses in the MS research field, where both 
infectious mononucleosis and antibodies against the Epstein-Barr nuclear antigen 1 (EBNA-1) 
have been associated with MS disease [95-98]. Also HHV-6A [64, 99-101] and HHV-6B [26, 
102] have been repeatedly associated with MS. For example, the HHV-6B protein 101K has 
been observed more frequently in oligodendrocytes in MS lesions compared to in normal 
appearing white matter from MS patients and controls [26, 102], indicating a role of the virus 
at disease site. Also, HHV-6A DNA has been observed in CSF of 22% of MS patients but in 0% 
of controls [100] and intrathecal anti-HHV-6A/6B IgG antibody production has been identified 
in approximately 25% of MS patients [60, 103]. When studying the role of HHV-6A and HHV-
6B during disease, Alvarez-Lafuente et al. [99, 104] have in several studies demonstrated a 
role of HHV-6A in disease activity as they observed higher HHV-6A viral DNA load in serum, 
and messenger RNA load in blood, during MS relapse compared to remission. The same group 
has also recorded an increase in anti-HHV-6A/6B IgM prior to relapse [61]. Since IgM 
antibodies are regarded as markers of recent reactivation or primary infection, the increased 
anti-HHV-6A/6B IgM prior to relapse suggests that the observed HHV-6A reactivation during 
relapses may have had a trigging effect on the relapse onset rather than being a consequence 
of it. Also suggestive of a role in disease onset, another group observed increased levels of 
IgM antibodies against HHV-6A/6B in early MS stages [105]. Thus, the association between 
viral infections and MS is interesting, but it is still unclear how such triggering mechanism 
would work. Three suggested mechanisms for viral triggering of autoimmunity are molecular 
mimicry, bystander activation and epitope spreading (reviewed in [106]). Another theory is 
that virus-incorporation of host cell proteins can induce autoimmunity against the 
incorporated molecules [107] (more about this hypothesis in section 4.4.6). 
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Not only is the trigger of MS unclear, but also the pathological processes by which the immune 
system interacts and degrades the myelin is complex and not fully understood. An extensive 
focus has been set on understanding the T cell mediated pathogenesis in MS, but the role of 
B cells and other cell types has received increased attention in the last few years. T cells are 
located within the MS lesions in early stages of MS disease, and the main CD4+ T cell subsets 
are TH1 and TH17. CD8+ T cells are also found in lesions and their number correlates with 
axonal damage. There is not only one specificity of these cells but the main specificity is 
thought to be against different myelin proteins (reviewed in [87]). B cells have received 
increased attention lately as treatment with B cell depleting anti-CD20 antibodies decreases 
disease activity [108-110].  
1.3.2 Epilepsy 
Epilepsy is a disease characterized by uncontrolled over-excitatory activity of neurons, which 
results in seizures and convulsions. There are different causes for the disease and in many 
cases the etiology is unknown. Epileptic seizures can be explained by electric discharges of 
the neurons that cannot be turned off. This could be due to an impairment of the neurons 
themselves or lack of regulation from the supporting glial cells, e.g. astrocytes. To date, there 
is no cure for epilepsy, but the seizures can be controlled by drugs. In severe medically 
refractory epilepsy, surgery is used to remove the part of brain tissue from where the seizures 
originate. 
High HHV-6B viral DNA load has been observed more frequently in surgically removed 
hippocampus tissue from mesial temporal lobe epilepsy (MTLE) patients than in non-epileptic 
tissue [111-114], indicating an association between the virus and epilepsy. In the epileptic 
tissue, HHV-6B has been found active in astrocytes [111, 112]. Astrocytes are the supporting 
cells of the brain with many functions including provision of nutrients to neurons and clearing 
of neurotransmitters in the brain so that the signaling between neurons can be terminated. 
Interestingly, HHV-6B infected astrocytes have dysregulated glutamate uptake [115]. 
Glutamate is an excitatory neurotransmitter and its extracellular levels need to be tightly 
regulated [116], hence deficient glutamate clearing by infected astrocytes might be one 
mechanism that could explain epileptic symptoms. Indeed, epileptogenic hippocampus has 
abnormally high levels of extracellular glutamate [117], indicating insufficient glutamate 
clearing in the epileptic tissue. 
In recent years, it has been suggested that epigenetic modulations may play a role in epilepsy 
[118, 119]. For example, the methylating enzymes DNMT1 and DNMT3a are strongly 
expressed in epileptogenic brain tissue from temporal lobe epilepsy patients, but only weakly 
expressed in control brains [120]. More methylation would generally indicate less gene 
expression in epileptic tissue, and indeed, hippocampi of temporal lobe epilepsy patients have 
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less expression of glutamate transporters [121]. However, none of these studies investigated 
the presence of viruses in the tissue.   
1.4 EPIGENETICS 
All cells of one individual carry exactly the same genetic code. However, the phenotype of 
different cell types varies enormously. This is because “epigenetics”, which could be explained 
as information associated with the DNA, but not encoded by the DNA sequence itself, affects 
the expression of the genome hence creating the cell phenotype. This information is generally 
inherited from mother cell to daughter cell so that the cell phenotype remains after cell 
division. However, the epigenetic code can be altered by environmental factors like stress, 
infections, diet, smoking and physical activity (reviewed in [122-126]). 
The two most studied mechanisms controlling epigenetic changes are DNA methylation and 
histone modifications. There is an interaction between different epigenetic regulating factors 
and several epigenetic modifications are needed for a strong effect. There is for example a 
strong correlation between DNA methylation, histone deacetylation, tightly packed 
chromatin and transcriptional repression (reviewed in [127]). 
1.4.1 DNA methylation  
DNA methylation is when a methyl group is covalently added to the carbon-5 position of a 
cytosine base in the DNA. This cytosine then becomes a 5-methylcytosine (5mC). The methyl 
transfer is executed by DNA methyltransferases (DNMTs) and primarily occurs at CpG sites, 
i.e. where the cytosine nucleotide is followed by a guanine nucleotide separated only by a 
phosphate. There are different DNMTs; DNMT1 is a key player in maintaining methylation 
marks after genome replication, while DNMT3a and DNMT3b can induce new methylation 
marks (de novo methylation) [128].  
Even though methylation is regarded as a relatively stable modification, methylated cytosines 
can be de-methylated. This can happen by passive de-methylation or by active oxidation 
executed by ten-eleven translocation (TET) enzymes (Figure 7). Passive de-methylation refers 
to lack of methyl groups or methyl donners, or absence of DNMTs. In active de-methylation, 
oxidization of the methyl group of 5mC to hydroxymethyl, formyl or carboxyl groups will 
convert 5mC to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) or 5-carboxy-
cytosine (5caC). These oxidized products will then be converted to unmethylated cytosine 
(reviewed in [129, 130]).  
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Figure 7: Major DNA methylation and demethylation pathways in mammals. DNMTs = DNA methyl-
transferases; TET = ten eleven translocation enzymes; SAM = S-adenosylmethionine; TGD = thymine 
DNA glycosylase; BER = base excision repair. Reprinted from Trends in Genetics, 2014, 30(10): 464-474 
[129] with permission from Elsevier. 
1.4.2 DNA methylation during virus infection 
The host epigenetic machinery is used in the defense against viruses in order to silence their 
transcription. It has been suggested that latencies of several herpesviruses are regulated by 
epigenetic mechanisms [131-133]. Both DNA methylation and histone modifications are 
involved in this regulation but this section will focus on DNA methylation as this is the focus 
in Study III. DNA methylation has been observed to regulate expression of many genes in the 
Epstein-Barr virus (EBV) genome, a way to control latency of this virus [134, 135]. DNA 
methylation has also been suggested to play a role during human cytomegalovirus (HCMV) 
latency as inhibition of DNA methylation activates silenced HCMV promoters [136]. In 
addition, non-susceptible cells became susceptible to HCMV infection upon inhibition of DNA 
methylation, indicating that the host cell methylation machinery is needed in the anti-HCMV 
defense during infection [137].  
As pathogens usually do, viruses have evolved strategies to overcome the immune regulation 
by the host, for example to use the epigenetic machinery for their own survival (reviewed in 
[123, 131, 138]). Esteki-Zadeh et al. [137] observed that HCMV affects the host DNA 
methylation capacity by inducing re-localization of DNMTs from the nucleus to the cytosol, 
hindering these enzymes to execute their methylating function. This re-localization induced 
global hypomethylation in the infected cells (i.e. less methylation compared to control), 
primarily due to an increase of un-methylated virus DNA. Virus modulation of the epigenetic 
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machinery can have severe implications for the host cells as many genes can be affected. One 
example is cancer caused by EBV infection, where EBV induces expression of DNMT3b, 
resulting in increased DNA methylation and decreased expression of many important host cell 
genes [139, 140]. To date, there are no publications investigating how HHV-6A and HHV-6B 
affect host cell DNA methylation. However, as other herpesviruses affect host cell DNA 
methylation it is plausible that HHV-6A and HHV-6B also has this capacity. The effect of HHV-
6B on host cell DNA methylation was investigated in Study III.  
1.5 GENETIC ASSOCIATION TO INFECTION  
As the virus life cycle is dependent on host cells, the virus - host interaction is of interest. One 
question to answer is if genetic variations in the host genome can affect this interaction.   
The human genome is in general very similar between individuals. However, differences exist 
for example through insertions/deletions of genomic sequences and through copy number 
variations (i.e. repeated genomic sequences in different number of repeats). The most 
studied genetic differences are certain positions in the DNA that consist of different 
nucleotides in a population. These sites are called single nucleotide polymorphism (SNP) and 
they can be analyzed and associated to different outcomes, most often diseases.  
One approach is to investigate the genetic association between one selected SNP, presumably 
based on a hypothesis or previous results, and the infection of interest. Using this approach, 
an association between HHV-6A active replication, defined as serum HHV-6A DNA, and the 
SNP rs4774C in the CIITA gene (class II major histocompatibility complex transactivator, Also 
known as: MHC2TA) was detected [141]. This gene encodes a protein that acts as a 
transcriptional regulator of MHC class II gene transcription, indicating MHC presentation to 
be important in HHV-6A viral control.  
1.5.1 Genome Wide Association Studies (GWAS) 
Another approach for investigating genetic associations to the virus of interest is to do a 
hypothesis-free genome wide association study (GWAS). First, genotypes for numerous SNPs 
(e.g. approximately 600,000 SNPs in Study V) are determined using arrays. When obtaining 
this kind of huge data sets from the genotyping, the data first needs to be quality controlled. 
When all SNPs not fulfilling certain criteria have been removed, an association study is made.  
As each SNP is investigated for association with the trait, the number of associations 
calculated are enormous. This needs to be taken into account when calculating the statistics, 
as accepting a type 1 error of 5% often used in experimental studies would yield an 
unacceptable number of false positive associations. A standard p-value accepted for 
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significance in GWA studies is p<5x10-8. As the p-values need to be very low for significance, 
the included patients/controls need to be in great numbers. The power to detect a difference 
is also dependent on having a clear qualitative trait, e.g. correctly defined seropositive and 
negative individuals, or a correctly measured quantitative variable, e.g. antibody levels. 
SNPs can be in linkage disequilibrium (LD), i.e. in non-random association because of a nearby 
location in the genome which makes them inherited together more often than expected by 
chance [142, 143]. Regions in high LD can be called haplotype blocks. This structural 
architecture can be used when deciphering GWAS data as not all SNPs in the genome have to 
be genotyped. The awareness of LD is of highest importance when focusing on the MHC 
region where several different alleles can be located in one haplotype [144]. SNPs annotated 
to non-HLA genes within the MHC region may be significantly associated to the investigated 
trait only as a consequence of being in an associated HLA haplotype. Also outside the MHC 
region, one needs to consider that a non-causing SNP can be significantly associated to the 
trait of interest only because this SNP is in LD with a causing SNP not investigated.  
1.5.1.1 GWA studies and herpesvirus infections 
When investigating genetic association with virus infection, it may not be obvious how to 
define the groups to compare. As mentioned above, Martinez et al [141] used serum HHV-6A 
DNA as a marker of active HHV-6A infection. It is however hard to find enough patients with 
this trait to do a full GWAS. As mentioned in section 1.1.2, an accurate latent or active 
infection status of one individual depends on sampling strategy and might not classify the 
patients correctly. A more indirect way is to measure antibody response against the virus of 
interest. However, this induces the uncertainty of what is genetically associated to the virus 
pathology and what is associated to the ability of the host to mount an antibody response.   
Rubicz et al [145] investigated the genetic associations to antibodies against several common 
viruses, for example against HHV-6B lysate, in a GWAS. They observed no significant 
association between HHV-6A/6B serostatus and investigated SNPs. Another study by Hammer 
et al [146] found that the IgG response against the EBV nuclear antigen 1 (EBNA-1), the 
Influenza A virus and the major capsid protein VP1 from JC virus was associated to SNPs in the 
MHC region. They could specifically pinpoint these genetic associations to amino acid residues 
in MHC class II proteins likely causing the association with antiviral antibody response against 
these viruses. As expected, the associations were virus-specific and not similar between all 
anti-viral responses.    
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2 AIMS 
 
The overall aim of this thesis was to increase the knowledge of HHV-6A and HHV-6B in relation 
to epilepsy and MS. 
Specific aims: 
Study I and II: To get better control over the experimental settings and increase the accuracy 
of the results. More specifically, the aim of Study I was to develop a robust and correct titer 
determining assay and the aim of Study II was to analyze stability of different reference genes 
in order to determine the most suitable reference gene to use in relative gene expression 
analyses in HHV-6B experiments.  
Study III: To investigate how HHV-6B affects DNA methylation. In addition we aimed to 
explore if DNA methylation changes induced by HHV-6B can have a pathogenic role in epilepsy 
or a role in the virus integration process. 
Study IV: To investigate the association between anti-HHV-6A/6B IgG response and MS 
disease. 
Study V: To develop a more specific antibody measurement and further investigate the role 
of HHV-6A and HHV-6B in MS. In addition, we aimed at exploring the genetic associations to 
the measured anti-viral IgG response. 
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3 MATERIAL AND METHODS 
3.1 STUDY I  
3.1.1 Study design 
The most basic information required when carrying out experiments with pathogens is how 
infectious the batch is that you’re working with. Culturing of HHV-6A in HSB-2 cells is a skill 
and we had problems with low infectious virus batches and no suitable method to measure 
what we were working with. There is no accepted standard measurement of HHV-6A/6B 
virulence and we were in great need of an easy, robust and correct measurement. So, what 
were the options?  
Plaque forming assays used for other viruses like HCMV [147] are not possible as HHV-6A and 
HHV-6B do not induce plaque formation. Also the fact that these viruses primarily infect T 
cells which are in suspension and not adherent induces some limitations. 
Another way to measure virus titers is to use the 50% Tissue culture Infective Dose (TCID50) 
endpoint dilution assay [148]. The interpretation of infectivity in this assay can be made with 
different readouts. The most common way to check for HHV-6A and HHV-6B infected cells is 
to look for enlarged cells (i.e. CPE) in a microscope. However, this is subjective and can be 
influenced by what one wants to see. The evaluation of CPE also relies on experience of 
assessing HHV-6A/6B infection in the cells of choice as even uninfected cells can become a bit 
“enlarged”. Also, there are size differences between the cell lines used for HHV-6A and -6B 
propagation. We had used ocular inspection when propagating virus batches in order to 
follow infection, but it did not seem to correlate very well with the infectivity of the virus 
batch obtained in the end and we did not feel confident to use this readout in a virus titer 
determining assay. Expression of genes/proteins can be good markers of active infection and 
possible to use as readout for the TCID50 plate. However, investigating virus RNA includes both 
RNA purification and conversion to cDNA, plus the use of correct normalization. IFA staining 
of virus proteins includes fixation of cells, staining and manual counting of an enormous 
amount of cells in the microscope. We decided both these readouts to be too laborious.  
There is one method used by some researchers in the field called Infectious Units (Inf U) that 
is based on IFA staining of cells [149]. This method relies on the assumption that the cells have 
not changed in numbers during the incubation period, which can be a problem when 
investigating low-titer batches as the cells might divide during this time. In addition, the 
interpretation of the fluorescent signal of the cells can be a bit subjective as it is not always 
clear what is positive and negative in the microscope. 
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Some laboratories do not use biological assays at all, but instead use the amount of viral DNA 
copies in the virus batch as a measurement for infectivity. This relies on the assumption that 
all viral copies are from complete viruses able to infect a host cell, which we did not believe 
in.  
In the end, we chose to optimize the classical TCID50 assay and developed a new PCR based 
readout.   
3.1.2 Cell culture and HHV-6A propagation 
A vial containing passage 10 of the HHV-6A GS strain, which had been stored since 1987, was 
kindly provided from Helena Dahl at the Swedish Institute for Infectious Disease Control, and 
propagated in the T-cell line HSB-2 using GlutaMAX containing RPMI 1640 medium (Gibco) 
supplemented with 10% fetal bovine serum (FBS) (HyClone), 100 U/ml penicillin and 100 
μg/ml streptomycin mixture (PEST) (Invitrogen), referred to hereafter as RPMI complete 
medium. When approximately 50% of the live cells were enlarged, the culture was spun at 
280 x g for 10 minutes and the supernatant collected and frozen immediately in aliquots in     
-80°C until analysis. Fractions of HHV-6A passage 17 (P17) were inactivated by UV- or heat- 
treatment for 20 min or 1 h at 56°C respectively.  
3.1.3 TCID50 method with different readouts  
In order to determine the optimal time when to analyze our TCID50 assay, a growth curve was 
made. HSB-2 cells were inoculated with different amount of HHV-6A and samples were 
collected at different time points. DNA was extracted simultaneously from cell suspension 
using a commercial 96-well magnetic bead based kit according to the manufacturer’s protocol 
(MagMAX-96 Viral RNA Isolation Kit, Applied Biosystems). DNA load was analyzed by real time 
quantitative PCR (qPCR) (7500 Fast Real-Time PCR System, Applied Biosystems) using primers 
for an immediate-early gene previously described [150]. Based on this growth curve, we chose 
7 days post infection (dpi) as the end point. TCID50 plate setup is visualized and described in 
Figure 8. 
At 7 dpi, the stored 0 dpi culture plate was thawed and cell suspension from every well from 
the both time points was added onto the same DNA extraction plate enabling the entire 
extraction procedure to be completed within 1 hour. Thereafter, the viral DNA was quantified 
by qPCR as described above. Wells where the viral DNA load had increased ten times at 7 dpi 
as compared to 0 dpi were considered as infected. The TCID50 was calculated according to the 
classical formula by Reed and Muench [148]. The units obtained are in the format of TCID50/ml 
and interpreted as the dilution giving infection in 50% of the wells. For example, a 1215 
TCID50/ml means that if 1 ml of a 1:1215 dilution of this batch is added to wells (containing 
cells as in the TCID50 plate), 50% of the wells will contain infected cell cultures. 
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Figure 8: TCID50 plate setup. 160 µl of the examined 
virus batch was added in sextuplicate wells to the 
first column of a round bottom 96 well culture plate 
and titrated in five-fold dilution steps. Then 104 HSB-
2 cells (40µl) were added to each well and after 
incubation and washing of the plate, fresh RPMI 
complete media was added after which cell 
suspension was sampled from every well and stored 
in -80°C. The remaining cell suspensions were 
incubated for 7 days at 37°C and 5% CO2. 
 
 
In order to investigate the accuracy of our PCR-based readout, we wanted to compare our 
results with results obtained with other methods from the same plates, also at 7 dpi. All TCID50 
plates were assessed by ocular inspection for enlarged cells using a phase contrast 
microscope by two independent inspectors. Wells where at least one enlarged cell was found 
were considered as infected. Viral protein expression was investigated with IFA on cells from 
every well of six TCID50 plates. The cells were fixed onto glass slides with a 1:1 mixture of 
acetone and methanol at -20°C for 10 minutes, thereafter blocked with 5% goat serum in PBS 
with 3% BSA. Staining was performed using primary mouse monoclonal antibodies specific to 
the HHV-6A/6B viral glycoproteins gp116/54/64 (1:60, Tebu-bio). The staining was visualized 
by an Alexa 633 conjugated secondary goat anti-mouse IgG (1:1000, Invitrogen). In addition, 
cell nuclei were stained with DAPI (Vector laboratories). Wells where at least 2% of the cells 
contained viral proteins were considered as infected.  
In order to compare stability of the methods, coefficient of variation (CV) was calculated 
(Formula 1). Variation of the readout, i.e. intra-assay CV, was calculated by comparing 
repeated measurements of one readout for one plate. Variation between plates, i.e. inter-
assay variation, was calculated by comparing the results obtained for one virus batch using 
the same method.  
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶 𝑣𝑣𝑣𝑣𝑣𝑣𝐶𝐶𝑣𝑣𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 (𝐶𝐶𝐶𝐶) =  𝑠𝑠𝐶𝐶𝑣𝑣𝐶𝐶𝑠𝑠𝑣𝑣𝑣𝑣𝑠𝑠 𝑠𝑠𝐶𝐶𝑣𝑣𝐶𝐶𝑣𝑣𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶
𝑣𝑣𝑣𝑣𝐶𝐶𝑣𝑣𝑣𝑣𝑎𝑎𝐶𝐶
 
 
Formula 1: Coefficient of variation (CV). CV is a measurement of variation among a set of values. CV 
can be given as % CV, i.e. the calculated CV x100.  
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3.1.4 Other titer determinations  
Assessment of Inf U by IFA was performed as previously described [149]. Briefly 2.5x105 un-
infected HSB-2 were inoculated as described above with 100 µl of undiluted or 10, 50 or 100 
times dilutions of HHV-6A in triplicate wells. The plate was incubated for two days before the 
cells were fixed onto glass slides and stained for the early viral protein p41 (1:50, Santa Cruz 
Biotech. Inc.). The viral titer, expressed as infectious units per ml, was calculated by 
multiplying the fraction of infected cells with the total number of cells at 0 dpi and with the 
dilution factor. 
As a comparison to these titer-determining assays mentioned above, the number of DNA 
copies were also determined in the virus batch. DNA was extracted from the virus batch using 
a commercial kit (QIAamp Viral RNA Mini Kit, QIAGEN) according to the manufacturer’s 
instructions. The viral DNA load was quantified with qPCR as described above but with the 
addition of a standard curve with known number of HHV-6A DNA copies.  
3.2 STUDY II-III 
3.2.1 In vitro experiments (Study II – III) 
HHV-6B strain Z29 was propagated in the Molt-3 T-cell line. Virus-containing cell free 
supernatant was obtained by centrifugation for 15 min at 280 x g when the cytopathic effect 
in the cell culture was >50%, and aliquots were stored at -80°C. Supernatant from uninfected 
Molt-3 cells was harvested in the same way as for the virus-infected cells and used as mock 
in subsequent experiments. Virus titers were determined using the qPCR readout of the 
TCID50 method described in Paper I, although changing the HSB-2 cells to Molt-3 cells and the 
HHV-6A specific primers to HHV-6B specific primers [151]. 
Molt-3 cells were incubated with mock or HHV-6B at a multiplicity of infections (MOI) of 0.01 
and 0.001 for 3h before medium was changed to fresh RPMI medium supplemented with 
GlutaMAX (Gibco), 1% PEST (Gibco) and 10% FBS (Gibco), and further cultured in the presence 
of 5% CO2 at 37°C. Three separate experiments were started at different days, each containing 
triplicate cultures for all conditions.  
All cell cultures were stained for the viral protein p41 (Santa Cruz Biotechnology) at 3 dpi 
yielding 96% (±1%) and 38% (±7%) positive cells in the HHV-6B cultures (0.01 MOI and 0.001 
MOI respectively) while 0% positive cells in mock-treated cells cultures. 
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3.2.2 In vivo material (Study III) 
As one of the original aims of the thesis was to investigate the role of HHV-6B in epilepsy, we 
wanted to investigate differences in epileptic tissue infected with HHV-6B compared to 
uninfected. To obtain material from epileptic brain surgery performed at Karolinska 
University hospital was found to be very hard. However, at the 7th international conference 
on HHV-6 & 7 in 2011 I had the opportunity to meet Dr. Pitt Niehusmann, a neuropathologist 
working with HHV-6A/6B in epilepsy at University of Bonn Medical Center. A collaboration 
was initiated and he sent purified DNA and RNA from their MTLE cohort, already investigated 
for presence of different viruses, including HHV-6B [152]. Twelve patients positive and 12 
patients negative for HHV-6B DNA in their surgically removed epileptic brain tissue were 
selected for inclusion in Study III. For detail see Supplementary table 1 in Study III. 
3.2.3 Measuring DNA methylation (Study III) 
3.2.3.1 Illumina 450K array  
Methylation was investigated for >485,000 CpG sites with the Infinium 
HumanMethylation450 BeadChip array according to manufacturer’s guidelines (IIllumina). 
This was done by the core facility BEA, Bioinformatics and Expression Analysis, at Novum, 
Karolinska Institutet. DNA samples from 24 brain biopsies and six DNA samples from one in 
vitro experiment (3 mock and 3 HHV-6B infected Molt-3 cultures harvested 3 dpi) were 
diluted and sent for analysis. Files were received from BEA containing normalized, 
preprocessed, QC checked and analyzed values. Both beta and M values were obtained but 
the M values were used as they are more accurate to use for statistics compared to beta 
values [153]. As always when performing multiple comparisons in the statistical analysis, 
the statistics need to be adjusted for that. In study III, the Benjamini-Hochberg procedure 
was applied and a false discovery rate (FDR) <0.05 was regarded as significant. 
Annotations were made against the genome version GRCh37/hg19, and this version was 
used for obtaining chromosome lengths and when investigating the data. 
3.2.3.2 Bisulfite pyrosequencing 
Results from large arrays, like the Illumina array used in this study, should always be 
technically validated in order to trust the obtained results from the array. Therefore, 
significant CpGs with large difference in M value were selected for validation using bisulfite 
pyrosequencing on new triplicate samples. Primers for five regions were designed in 
PyroMark Assay Design 2.0 (Qiagen), which would in total give methylation information about 
9 CpGs from the Illumina array and 16 additional CpGs present in the analyzed regions. To 
investigate DNA methylation with the pyrosequencing technique, the template DNA first has 
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to be bisulfite converted. This was done using EZ DNA Methylation-Gold™ Kit (Zymo Research) 
according to manufacturer’s protocol. This procedure will convert all unmethylated cytosine 
residues to uracil, but leaves 5mC unaffected. When sequencing the DNA on the PyroMark 
Q96 ID machine (Qiagen), this change in nucleotide will tell if the specific position is 
methylated or not. 
The ordered primers were first optimized for the best annealing temperature. As template, 
20ng bisulfite converted Molt-3 DNA was amplified according to manufacturer’s protocol 
(Qiagen) but using three different annealing temperatures in the PCR program. The best 
temperature was chosen using agarose electrophoresis looking for the sharpest band on the 
gel. All primer pairs yielded sharp bands and were regarded as suitable to use.  
In the next step a “bias test” was performed, i.e. % methylation was investigated with 
pyrosequencing on amplified DNA with known methylation status (Qiagen). In this step, 
several CpGs had to be excluded. For example, the methylation status on CpGs in the analysed 
DOC2B region did not yield correct results (Figure 9A). This non-linear, incorrect methylation 
status was also confirmed in a second experiment using more dilutions in the 50-100% 
methylated region (data not shown) and this primer pair was therefore excluded from the 
panel. This is a perfect example why the bias test was important, since usage of these primers 
would give unreliable results. Also, the read was shortened for one of the VPS53 regions as 
the read was long and only the first two CpGs “Passed” in the machine quality control and 
yielded expected % methylation (Figure 9B). Primer sequences of the included primers are 
stated in Paper III. 
 
Figure 9: Bias test of bisulfite pyrosequencing primers. Primers specific for regions in the A) DOC2B 
B) VPS53 genes. Red color indicates that these CpG sites were excluded from further analysis. 
 
When optimization was done, triplicate mock and HHV-6B infected Molt-3 samples were 
analyzed with the optimized primers. One CpG was followed in triplicate samples over time.  
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3.2.4 Measuring gene expression (Study II – III) 
We wanted to investigate the expression of genes with HHV-6B induced change in DNA 
methylation. However, it is not sufficient to investigate only the gene of interest as that will 
highly depend on the input of cDNA. The most common way of presenting gene expression is 
by “relative gene expression” where the gene of interest is normalized to a reference gene, 
i.e. a stable gene not affected by the experimental condition. As we did not know what 
reference gene that could be regarded to be stable during HHV-6B infection, we had to figure 
that out.  
All qPCR analyses were performed using TaqMan™ Gene Expression Assays according to 
manufacturer’s protocol in 384-well plates on a QuantStudio™ 7 Real-Time PCR System 
(Applied Biosystems). Each well contained 20 ng cDNA (except in efficiency tests) in a total 
volume of 12µl. All plates included 'no reverse transcription' and 'no template' control. 
3.2.4.1 Study II 
In order to find a suitable reference gene to use in Study III, eight genes previously 
investigated during HHV-6A infection [154] were investigated for suitability to use as a 
reference gene during HHV-6B infection.  
When investigating the expression of one gene in comparison to another, it is of highest 
importance that the PCR efficiency is similar for the two genes. If one gene amplifies the 
product at a higher rate compared to the other, the difference between them will vary with 
the cDNA concentration used. The eight investigated reference gene assays had very similar 
efficiency (Average = 86% ±2%; 2% CV), calculated based on the slopes visualized in Figure 10. 
The efficiency is generally accepted if 90-110%, but the efficiency is highly dependent on e.g. 
the pipet used and we believe it is more important that the assays are similar than to be exact 
within the suggested range.  
𝐸𝐸𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐸𝐸 (𝐸𝐸) =  10−1/𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 − 1 
 
Figure 10: PCR efficiency of investigated reference genes. Log10-transformed cDNA concentration 
plotted against the raw CT values. cDNA converted from total RNA extracted from uninfected Molt-3 
cells was used as template. Efficiency was calculated using the stated formula. 
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As all eight TaqMan assays had similar efficiency, and did not amplify the negative controls, 
they were all included for investigation of stability during HHV-6B infection. In that step, 5 
uninfected (0 dpi), 5 mock- and 5 HHV-6B-infected (3 dpi) samples were used. Stability of the 
genes was investigated using four different methods. These were the 2-ΔΔCT method [155] 
(Formula 2) and the three algorithms BestKeeper [156], GeNorm [157] and NormFinder [158]. 
 
∆𝐶𝐶𝑇𝑇(𝐶𝐶𝑣𝑣𝑐𝑐𝐶𝐶𝑐𝑐𝑐𝑐𝑣𝑣𝐶𝐶𝐶𝐶𝑠𝑠 𝐶𝐶𝐶𝐶𝑣𝑣 𝐶𝐶𝑣𝑣𝐶𝐶ℎ 𝑠𝑠𝑣𝑣𝑠𝑠𝑠𝑠𝑐𝑐𝐶𝐶/𝐶𝐶𝑣𝑣𝑐𝑐𝐶𝐶𝑐𝑐𝑣𝑣𝑣𝑣𝐶𝐶𝐶𝐶𝑣𝑣) = 𝐶𝐶𝑇𝑇 𝐶𝐶𝑣𝑣𝑣𝑣𝑎𝑎𝐶𝐶𝐶𝐶 𝑎𝑎𝐶𝐶𝐶𝐶𝐶𝐶 − 𝑁𝑁𝑁𝑁    ∆∆𝐶𝐶𝑇𝑇(𝐶𝐶𝑣𝑣𝑐𝑐𝐶𝐶𝑐𝑐𝑐𝑐𝑣𝑣𝐶𝐶𝐶𝐶𝑠𝑠 𝑠𝑠𝐶𝐶𝑠𝑠𝑣𝑣𝑣𝑣𝑣𝑣𝐶𝐶𝐶𝐶𝑐𝑐𝐸𝐸 𝐶𝐶𝐶𝐶𝑣𝑣 𝐶𝐶𝑣𝑣𝐶𝐶ℎ 𝑎𝑎𝐶𝐶𝐶𝐶𝐶𝐶) = ∆𝐶𝐶𝑇𝑇 𝑠𝑠𝑣𝑣𝑠𝑠𝑠𝑠𝑐𝑐𝐶𝐶 −  ∆𝐶𝐶𝑇𝑇 𝐶𝐶𝑣𝑣𝑐𝑐𝐶𝐶𝑐𝑐𝑣𝑣𝑣𝑣𝐶𝐶𝐶𝐶𝑣𝑣  
𝑅𝑅𝐶𝐶𝑐𝑐𝑣𝑣𝐶𝐶𝐶𝐶𝑣𝑣𝐶𝐶 𝐶𝐶𝑒𝑒𝑠𝑠𝑣𝑣𝐶𝐶𝑠𝑠𝑠𝑠𝐶𝐶𝐶𝐶𝐶𝐶 =  2−∆∆𝐶𝐶𝑇𝑇 
Formula 2: 2-ΔΔCT method used to calculate relative expression of all investigated reference genes in 
study II. CT = threshold cycle, i.e. the value reflecting how many amplification cycles that are needed 
to reach the set threshold in the PCR machine. NF = normalization factor, the geometric mean of all CT 
values obtained for all reference genes (except TBP as this gene was not suitable as reference gene). 
ΔCT Calibrator = Average ΔCT of the 5 uninfected 0 dpi Molt-3 samples.  
 
 
As expression of TBP was found to be altered by HHV-6B infection 3 dpi, we wanted to 
monitor this expression over time. To do that, we analyzed expression of this gene in triplicate 
samples obtained from 5 time points between 0 to 6 dpi. In this additional experiment, PPIA 
was used as reference gene as it was determined to be the most stable in expression during 
HHV-6B infection. 
3.2.4.2 Study III 
Expression of the four genes DOC2B, RPH3AL, RFLNB and VPS53 was investigated. As 
described above, efficiency was first evaluated. Efficiency of the RFLNB, VPS53 and RFLNB 
assay was very similar to the efficiency of the PPIA assays (≤5% CV), indicating that PPIA can 
be used as a reference gene when investigating RFLNB, VPS53 and RFLNB expression. 
However, the DOC2B gene was very low expressed and the obtained efficiency was not the 
same as for PPIA (21% CV, probably due to uncertainty of high CT values). As uninfected Molt-
3 cells did not obtain any CT values with the TBP gene expression assay, the accuracy of this 
gene was not further investigated. 
Based on the results presented in Study II, PPIA was used as a reference gene in Study III. Five 
mock and five HHV-6B infected (3 dpi) samples were analyzed. In addition, VPS53 expression 
was further investigated over time in a separate experiment using new triplicate samples 
obtained day 0, 1, 2, 3 and 6. Relative expression was calculated with the 2-∆∆CT method using 
the average ΔCT for mock (3 dpi) or untreated (0 dpi) as calibrator. 
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3.2.5 Investigation of virus integration (Study III) 
To investigate if the induced hypomethylation at 17p13.3 could be associated with HHV-6B 
integration into the telomeric region of chromosome 17p, a PCR method was used to amplify 
one of the recombination sites on one side of the virus. With one primer binding to 17p and 
the other primer binding to HHV-6B DRR, amplification of a ~1.5kb product indicates 
integration (Figure 11). 
 
Figure 11: Primer location. Approximate location of primers used in integration PCR. Black = telomere 
region, grey = subtelomere. DRL – U – DRR represent the virus genome (see section 1.1.1.3 for more 
info). Information adapted from [66]. Figure not in correct scale. 
 
Primer design was copied from Arbuckle et al. [66] but optimization was needed in order to 
ensure that the most suitable conditions were used. In the optimization step, 100ng DNA was 
used as template (mock or virus-infected Molt-3 cells 6 dpi). Three different annealing 
temperatures and two different primer concentrations were used, and amplified products 
were visualized with agarose gel electrophoresis.  A ~1.5kb DNA fragment was observed in 
the virus-infected sample, but not in the uninfected sample, when using the primer 
concentration 0.5 µM and an annealing temperature of 60 °C, hence this was the chosen 
condition in the next experiment. 
To investigate integration in our material, triplicate DNA samples of uninfected (0 dpi and 6 
dpi) and HHV-6B infected (1, 2, 3 and 6 dpi) Molt-3 cells were analyzed. 
3.3 STUDY IV-V 
3.3.1 Study participants  
All individuals included in Study IV and V were already included in other, ethically approved, 
studies. The aim of Study IV and V, i.e. to investigate risk factors for MS disease, was in line 
with the aim of the studies to which the study participants were recruited. All study 
participants provided written informed consent and the studies were performed according to 
the ethical standards of the Declaration of Helsinki. 
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3.3.1.1 Study IV 
The study participants (446 MS patients and 487 controls) included in study IV were all part 
of the Epidemiological Investigation of Multiple Sclerosis (EIMS, [92]) study cohort. Treatment 
data was obtained for 368 MS patients from the national Swedish MS registry [159]. For 
detailed information regarding the included cohorts, see Table 1 in Study IV. 
3.3.1.2 Study V 
Two different patient cohorts were used in Study V, one with samples taken during MS 
disease and one where the samples analyzed had been collected before MS diagnosis.  
The established MS cohort included the 916 EIMS participants analyzed in Study IV, but the 
number of study participants was greatly increased in Study V. In total, 8526 MS patients and 
6932 controls matched for age, gender and residency were included from the EIMS study 
(n=5266), Genes and Environment in Multiple Sclerosis (GEMS [160], n=8940), 
Immunomodulation and Mutiple Sclerosis Epidemiology study (IMSE [161], n=1152) and 
Stockholm Prospective Assessment of Multiple Sclerosis (SPASM/STOPMS [162], n=100) study 
cohorts (Table 1 in Study V).   
The pre-MS cohort was a prospective case-control study on biobank samples drawn before 
symptom onset (Table 2 in Study V). The Swedish MS registry [159] was crosslinked with three 
Swedish microbiological biobanks. These biobanks contained the remainders of sera after 
clinical microbiological analyses performed at the University Hospitals of Skåne and Göteborg, 
and the Public Health Agency of Sweden. The pre-MS patient samples were collected from 
individuals less than 40 years of age who later developed RRMS (n=480). Individuals who did 
not develop MS served as controls (n=480). Controls were matched for biobank, sex, date of 
blood sampling and date of birth.  
3.3.2 Generating data 
3.3.2.1 Measurement of anti-HHV6A/6B IgG (study IV) 
As no method was available for measuring antibodies specific for either HHV-6A or HHV-6B 
when study IV was planned, we chose to investigate the anti-HHV-6A/6B IgG response with a 
commercial anti-HHV-6 IgG Antibody ELISA Kit according to the manufacturers’ protocol 
(Advanced Biotechnologies). The antigen in this ELISA was whole HHV-6B virion lysate, but as 
most of the viral proteins are very similar between HHV-6A and HHV-6B this assay measures 
antibody responses against both virus species.  
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All plasma samples (n=933) were run in duplicate wells and approximately equal number of 
case and control samples were analyzed on all plates. The titer results are given as normalized 
optical density (OD) ratios, calculated by ODsample divided by 2xODneg control. As suggested in the 
assay protocol, OD ratios ≤0.75 were regarded as negative and OD ratios ≥1.00 as positive. 
Borderline samples (OD ratio 0.76 - 0.99, n=36) were excluded from the antibody prevalence 
analysis but included when titers were analyzed. The positive control’s OD ratio on all plates 
had an inter-assay CV of 13% indicating a stable assay.  
3.3.2.2 Measurement of anti-p41 IgG and total IgG (study IV) 
To investigate the specificity of the anti-HHV-6 antibodies, samples from 67 RRMS patients 
and 67 controls (Table 1B in Study IV) were further examined for IgG specific for the HHV-
6A/6B early antigen p41 and for total plasma IgG levels. These samples were selected based 
on equal anti-HHV-6A/6B IgG titers and were matched for gender, HLA-A*02 status and 
smoking habits. In addition to the 134 samples, plasma samples from 8 MS patients and 8 
healthy controls which were negative for anti-HHV-6 IgG were also investigated for total IgG. 
Commercial ELISA kits were used for detection of IgG against p41 according to manufacturer’s 
protocol (Bioworld Consulting Laboratories). Results were obtained as OD ratios and 
interpreted as above. Total IgG was measured using Human IgG ELISA kits (ALP) according to 
protocol (Mabtech). All plasma samples were run in duplicate wells. 
3.3.2.3 Measurement of anti-IE1A, IE1B and 101K IgG (study V) 
In order to study the anti-HHV-6A/6B IgG response more in detail, a new method was used to 
measure IgG antibodies specific for viral epitopes selected to be as divergent between HHV-
6A and HHV-6B as possible. This method is a multiplex Luminex assay that uses beads coated 
with recombinant glutathione s-transferase (GST) fusions proteins allowing simultaneous 
measurement of numerous IgG specificities at the same time. The exact assay procedure has 
been described in detail elsewhere [163] and simplified in Study V. Antibody responses 
against four different HHV-6 protein sequences were analyzed. These were the HHV-6A and -
6B specific parts of the immediate early protein 1, IE1A and IE1B respectively, and HHV-6A 
and -6B specific parts of the structural protein 101K (HHV-6B) and p100 (HHV-6A). Due to low 
reactivity against p100, this epitope was removed from further analysis. A Luminex 100 
analyzer was used to measure the fluorescent signal and the results are expressed as median 
fluorescence intensity (MFI).   
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3.3.3 Analysis of data 
3.3.3.1 Cutoff for seropositivity 
For the ELISA kits used in study IV, the cutoffs for seropositivity were included in the kit 
manuals. However, for the Luminex assay, we had to decide what cutoff values to use in order 
to determine the serostatus. This was done by correlating the Luminex MFI results with the 
ELISA OD results obtained in Study IV (n=916), presuming that the ELISA measures IgG 
antibodies specific for all viral epitopes and that these values were “correct”. For each 
antigen, the serostatus cutoff was determined to be where the specificity and sensitivity was 
best. In addition, a 5% exclusion was added so that two cutoffs were used when measuring 
seropositivity. The samples with MFI above the higher cutoff were regarded as seropositive 
and the samples with MFI value below the lower cutoff were seronegative while samples with 
values in between the cutoffs were excluded from serostatus analysis.  
3.3.3.2 Transformation 
As the obtained antibody distribution was skewed in both Study IV and V, the antibody levels 
were transformed before statistical analyses with linear regression models were performed. 
This was done using the Box-Cox power transformation in STATISTICA 11 in Study IV and a 
Log10-transformation in R in Study V. As an example, the distribution of untransformed and 
Log10-transformed anti-IE1A IgG levels are visualized in Figure 12.  
 
 
Figure 12: Histogram before and after Log10-transformation of anti-IE1A IgG levels. X-axis show MFI. 
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3.3.3.3 Statistics 
The statistical analyses are similar in paper IV and V, but in paper IV nonparametric tests 
(Mann Whitney U or Kruskal-Wallis ANOVA and Pearson’s chi-squared tests) were used as 
primary calculations and linear regression models as a way to confirm the results and to test 
the effect of potential confounders. In paper V, the regression models were the primary 
statistical measurement and nonparametric tests only performed as one sub-analysis. Also, 
in paper V the primary focus was on logistic regression models with serostatus as dependent 
variable, which was not used in paper IV. The main advantage with the regression analyses is 
that potential confounders can be added to the model and adjusted for. The cohorts were 
adjusted for slightly different variables as different information was available for use, but all 
models were adjusted for age at sampling and gender (see the articles for exact information). 
The threshold for significance was set at p <0.05 in both paper IV and V.  
The presentation of our logistic regression results focus both on the obtained p-values and 
the Odds ratios (OR). OR is often used to report an association between an exposure and an 
outcome. In study V the serostatus for each epitope was used as “exposure” and MS disease 
as an outcome (Formula 3). Together with the point estimate of OR, the 95% confidence 
interval (CI) is presented, which yields a good indication on the strength of the presented OR. 
If the 95% CI spans over the number one, the association is not statistically significant. In 
addition to the OR and 95% CI, p-values obtained from the logistic regression models were 
presented to show the significance of the association.  
 
 
𝐀𝐀)    𝑂𝑂𝑅𝑅 = (𝐶𝐶𝑐𝑐𝑠𝑠𝑐𝑐𝐶𝐶𝑣𝑣 𝐶𝐶𝐶𝐶 𝑠𝑠𝐶𝐶𝑣𝑣𝐶𝐶𝑠𝑠𝐶𝐶𝑠𝑠𝐶𝐶𝐶𝐶𝐶𝐶𝑣𝑣𝐶𝐶 𝑀𝑀𝑀𝑀 𝑠𝑠𝑣𝑣𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑠𝑠𝐶𝐶𝑐𝑐𝑠𝑠𝑐𝑐𝐶𝐶𝑣𝑣 𝐶𝐶𝐶𝐶 𝑠𝑠𝐶𝐶𝑣𝑣𝐶𝐶𝑠𝑠𝐶𝐶𝑠𝑠𝐶𝐶𝐶𝐶𝐶𝐶𝑣𝑣𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑣𝑣𝐶𝐶𝑐𝑐𝑠𝑠 )(𝐶𝐶𝑐𝑐𝑠𝑠𝑐𝑐𝐶𝐶𝑣𝑣 𝐶𝐶𝐶𝐶 𝑠𝑠𝐶𝐶𝑣𝑣𝐶𝐶𝐶𝐶𝐶𝐶𝑎𝑎𝑣𝑣𝐶𝐶𝐶𝐶𝑣𝑣𝐶𝐶 𝑀𝑀𝑀𝑀 𝑠𝑠𝑣𝑣𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑠𝑠 𝐶𝐶𝑐𝑐𝑠𝑠𝑐𝑐𝐶𝐶𝑣𝑣 𝐶𝐶𝐶𝐶 𝑠𝑠𝐶𝐶𝑣𝑣𝐶𝐶𝐶𝐶𝐶𝐶𝑎𝑎𝑣𝑣𝐶𝐶𝐶𝐶𝑣𝑣𝐶𝐶 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑣𝑣𝐶𝐶𝑐𝑐𝑠𝑠 )        
𝐁𝐁)    𝐸𝐸 =  𝑐𝑐0 + 𝑐𝑐1𝑋𝑋1 +  𝑐𝑐2𝑋𝑋2 +  𝑐𝑐3𝑋𝑋3           𝑂𝑂𝑅𝑅 = 𝐶𝐶𝑏𝑏1 
Formula 3: Calculation of Odds ratio (OR). A) The formula for manually counting OR, without any 
covariates. B) Logistic regression and how to convert the beta value into OR. y=dependent variable, 
i.e. MS in this study, X= investigated independent variables, b0 = intercept of the regression model, b1 
= slope of variable 1, e.g. serostatus. The interpretation of these examples would be: OR=1; Serostatus 
does not affect odds of MS disease, i.e. no association between seropositivity and MS disease. OR>1; 
Seropositivity is associated with higher odds of MS disease. OR<1; Seropositivity is associated with 
lower odds of MS disease.  
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3.3.3.4 GWAS 
GWA studies were performed in order to investigate the genetic association with the three 
measured anti-HHV-6A/6B epitope specific IgG responses. Genotypes were previously 
determined using Infinium OmniExpress BeadChips (Illumina). In order to assure the quality 
of all genotyped SNPs, SNPs with <2% minor allele frequency (MAF), SNPs genotyped in <98% 
of individuals, and SNPs not in Hardy-Weinberg equilibrium among controls (p<0.0001) were 
removed from further analysis. In addition, individuals with >2% failed SNP genotyping, 
individuals with increased heterozygosity (>mean+2SD), related individuals, or individuals 
where the recorded sex differed from their genotype were removed from analysis. Also, a 
principal component analysis was conducted using Eigensoft [164] in order to control for 
population stratification, and in order to identify and remove all population outliers. After 
quality controls, data on approximately 600,000 SNPs for 6,808 MS cases and 5,671 controls 
from the established MS cohort was included in the GWASs. 
Logistic and linear regression models for serostatus and antibody levels, respectively, were 
analyzed using PLINK v1.9 [165]. This was first done separately for MS cases and controls, 
followed by a meta-analysis. 
3.3.3.5 HLA-imputation and association between HLA haplotypes and antibody responses 
In order to determine association between the antibody responses measured in Study V and 
carriage of HLA alleles, SNP genotyping data was obtained from the MS Replication Chip. This 
chip contains approximately 90,000 SNPs chosen to densely cover the MHC region and 
because of previous association to MS.    
HLA allele variants for MHC class I and II were imputed by the software HLA*IMP:02 [166] for 
7,641 MS cases and 6,453 controls. Associations between HLA alleles and serostatus or 
antibody levels against each HHV-6 antigen were determined by logistic and linear regression 
models using R version 3.3.1. Associated alleles were combined into haplotypes using 
previously reported common haplotypes in the Caucasian population. Analyses were 
stratified by MS affection status and adjusted for gender and age at sampling. 
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4 RESULTS AND DISCUSSION 
4.1 STUDY I 
When doing experimental research with viruses, it is important to know if the virus batch one 
has is infectious or not, and how much of this virus batch to add to the cell culture 
experiments in order to have the infectivity of choice. As no standard methods for measuring 
HHV-6A/6B infectivity was available, we aimed at developing a correct, robust and easily 
interpreted assay. 
We developed an HHV-6A specific TCID50-method and compared different readouts of the 
plate to each other. As seen in Table 1, the different readouts used yielded similar TCID50 
values. However, high inter-assay CV was obtained using all readouts, indicating large 
variation in the TCID50 assay itself. When comparing the TCID50 method to the Inf U assay we 
observed similar variation within the methods (inter-assay CV 73% for TCID50 with qPCR 
readout and 77% for the Inf U assay), indicating that a high variation might be expected when 
working with HHV-6A infection of HSB-2 cells.  
The qPCR readout correlates well with IFA readout indicating a correct result when analyzing 
DNA as a readout for positivity. The intra-assay variation was lowest for the qPCR readout (9% 
CV). This means that when extracting DNA from the same plate two times with subsequent 
different PCR amplifications, the results became similar, indicating a robust readout. The 
ocular inspection had the highest intra-assay CV (45% CV), confirming our impression of a 
subjective readout. 
 
 
Table 1: Results from different titer assessments. Inf U = infectious units, nd = Not done 
 
The P21 and P27 virus batches show very low TCID50 values, indicating few infectious virions 
per ml. However, the DNA load of P21 was similar to the more infectious batches, indicating 
TCID50/ml TCID50/ml TCID50/ml Inf U/ml HHV-6A
Virus batch Q-PCR Ocular inspection IFA IFA DNA cop/ml
P17 1215 ±566 (x3) 771 ±466 (x3) 972 ±719 (x2) nd 7.6e8 ±1.4e8 (x2)
P19 806 ±679 (x5) 465 ±408 (x5) 649 (x1) 2.5e4 ± 1.6e4 (x3) 16.0e8 ±1.3e8 (x2)
P21 6 ±8 (x2) 14 ±6 (x2) nd nd 7.7e8 ±0.15e8 (x2)
P27 7 ±6 (x3) 30 ±15 (x3) 13 ±3 (x3) 3.9e4 (x1) nd
P17 UV-inact. 0 (x1) 0 (x1) nd nd nd
P17 heat-inact. 20 (x1) 4 (x1) nd nd nd
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that measuring DNA load does not have to correlate with virus titer. Also, the Inf U assay 
yielded similar values for P19 and P21 indicating that this IFA-based assay might have low 
sensitivity and not be suitable to use for low-titer batches. 
4.1.1 Reflections 
In study II and III, the TCID50 assay with qPCR readout for HHV-6B was used (although the 
method is only validated for HHV-6A in Study I). To calculate MOI, i.e. the number of virus 
particles per cell, often used as a measurement of viral input in experimental settings, the 
TCID50/ml first needs to be converted to number of viable virions/ml. This was in study II and 
III done by multiplying the TCID50/ml with 0.69 (based on the Poisson distribution). The MOI 
0.01 was used meaning 0.01 viable virions per cell. This may be an underestimation as >95% 
of the cells were infected 3 dpi. This suspicion can be augmented when looking closer at the 
relationship between the Inf U results and the TCID50 results. The readout of the Inf U assay 
is infectious units (i.e. virions) per ml and should therefore, according to my way of converting 
be Inf U /ml = TCID50/ml x 0.69. If the Inf U results for P19 are “correct”, and the conversion 
can be made as stated above, the TCID50 should have been approximately 36,000 TCID50/ml. 
I am confident in the titer calculations made to obtain the TCID50 value/ml and suspect that 
the possible underestimated titer value is most probably due to the conversion to MOI. When 
looking back at these calculations I think it is more correct not to convert TCID50/ml to MOI, 
but instead specify the TCID50 added to each experimental condition, although this titer unit 
is hard to interpret.  
The Inf U assay is laborious with all IFA stainings and subsequent cell counting, but I believe 
an improvement of this assay could be a good option. One possible readout could be flow 
cytometry (FACS). However, this readout would need optimization to set criteria for positivity. 
Although our result of the Inf U assay indicate that it could not distinguish between our two 
tested virus batches, that might not be a problem if using more infectious virus batches or 
another readout. One major advantage of this assay is that the units obtained are easily 
interpreted.  
However, I believe that the exact titer might not be so important as long as there is a 
measurement of infection within the study experiment (for example % infected cells). The 
variations between laboratories will be large anyway due to different viral strains, cells and 
other conditions. On the other hand, a reliable titer determining assay is needed as it is of 
highest importance to keep track of titers within a lab in order to repeat experiments etc. 
In conclusion, I think that the TCID50 method can be a good choice and that the qPCR readout 
is a correct and robust readout, especially when the assessor is not used to visual inspection 
of infected cells. However, the TCID50 method might underestimate the titers and does not 
yield so easily interpreted titer units. 
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4.2 STUDY II 
In order to measure relative gene expression in experimental studies like Study III, we first 
had to determine what reference gene to use for normalization in order to obtain reliable 
results. Ideally, several stable reference genes should be used, however, having more genes 
results in greater costs and less space on an analysis plate. In addition, the GeNorm analysis 
used demonstrated little increase in reliability when using one or two reference genes during 
HHV-6B infection. Therefore, we decided to use only one in future experiments.  
We used four different analysis tools to determine reference gene stability and all gave similar 
ranking of the 8 investigated genes, with the exception for the standard deviation (SD) 
analysis in BestKeeper. This analysis relies on the assumption that the input cDNA is similar in 
all samples and that the expression of investigated genes should be stable, hence yield a low 
SD. This may be a good analysis when investigating for example a drug effect, but when 
working with infections this analysis should be interpreted with caution. As seen in Figure 13, 
we observed that the RNA load is increased in virus infected cell cultures, probably due to 
virus RNA being expressed. As the same amount of total RNA was transcribed to cDNA and 
used for expression analyses, the relative amount of the investigated reference genes is 
decreased in infected samples. Therefore a low SD of a reference gene indicates upregulation 
of this gene. 
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Figure 13: Average µg extracted RNA from 106 living cells over time in one experiment. Mean of 
triplicate samples. Total RNA measured with nanodrop and living cells were counted in 
hemocytometers under a phase contrast microscope.   
 
The gene ranking was similar between the different analyses, and results from the 2-ΔΔCT 
method are presented in Figure 14. According to this analysis; peptidylprolyl isomerase A 
(PPIA), ribosomal protein L13 (RPL13) and β-actin (ACTB) are most suitable as reference genes 
when normalizing expression data in HHV-6B infected Molt-3 cells. This figure also clearly 
visualizes the expressional difference of TATA-box binding protein (TBP) observed with all 
analysis tools. If using TBP as a reference gene, it is highly plausible that other genes will falsely 
appear downregulated.  
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Figure 14: Relative expression (2-ΔΔCT) of the eight investigated reference genes. Expression in mock 
(n=5) and HHV-6B (n=5) infected cells (3 dpi) compared to uninfected cells (0 dpi). TBP is not included 
in the NF used for calculations. Statistics from a two way ANOVA is presented: * = p<0.05, **** = 
p<0.0001. 
 
 
As TBP does not appear to be upregulated by other herpesviruses [154], it is likely a HHV-6B 
specific upregulation. The gene TBP is located close to the telomere at chromosome 6q 
(although not differently methylated by HHV-6B, data not shown) and the encoded protein 
binds DNA and can initiate transcription. If the observed expressional increase has any 
biological impact cannot be answered by our study. However, TBP has been found to co-
localize in the cell nucleus with the HHV-6B viral U94 [167] and DR6 proteins [168]. U94 is a 
latency associated protein described in section 1.1.3 and DR6 is a protein that delays cells in 
the G2/M-phase hence inhibit cell proliferation of host cells [169]. Also, TBP binding to DNA is 
increased during HHV-6B infection [168] and it is therefore highly plausible that the 
expressional increase observed in Study II is important in the HHV-6B biology.  
In conclusion, PPIA was chosen as a suitable reference gene to use in Study III and it would be 
interesting to further study the interaction between TBP and HHV-6B.  
4.3 STUDY III 
Viruses have been suggested to affect DNA methylation in host cells in various ways (for more 
info see section 1.4.2), however no information was available on how HHV-6B or HHV-6A 
affects DNA methylation. We chose to work with HHV-6B as this virus has been associated to 
epilepsy (see section 1.3.2) and we wanted to investigate possible pathogenic effects of this 
virus caused by epigenetic modifications. 
Using an Illumina 450K whole genome methylation array, we investigated approximately 
450,000 CpG sites at the same time. This array revealed that HHV-6B induces hypo-
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methylation, i.e. less methylation compared to controls, in the host cell genome (Figure 15). 
The distribution of hypomethylated CpGs did not appear random as it was primarily taking 
place close to the telomeres. This was most evident at the end of chromosome 17p where 
34% (138/406) of the significant CpG sites were located. 
 
 
Figure 15: Volcano plot visualizing the Illumina 450K results. Each dot represents one CpG site. A 
negative M value interprets as less methylation in virus infected Molt-3 cells compared to uninfected 
cells 3 dpi (i.e. hypomethylation), a positive M value interprets as more methylation in infected cells 
(i.e. hypermethylated). Values above the red line are significant (FDR<0.05). 
 
The observed HHV-6B induced hypomethylation was confirmed in new triplicate samples 
using bisulfite pyrosequencing. In addition, we wanted to investigate the temporal regulation 
of this epigenetic change. Methylation status of one CpG site in the VPS53 gene (cg20843650) 
was followed over time and was found to be hypomethylated 2 dpi (Figure 16A).  
In order to investigate if the observed virus-induced hypomethylation had any impact on gene 
expression, we chose to investigate expression of the four genes located in the 
hypomethylated region at 17p13.3: DOC2B, RPH3AL, RFLNB and VPS53. All of these four 
genes had higher expression level in HHV-6B infected Molt-3 cells compared to in mock-
treated cells, indicating a functional role of the DNA methylation. The expression of VPS53 
was followed over time and was found to be significantly upregulated already at 2 dpi (Figure 
16B). This similar time line for DNA methylation and gene expression indicates an association 
between the two measurements. 
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Figure 16: The effect of HHV-6B infection on the VPS53 gene over time. A) Methylation of cg20843650 
(VPS53) measured with bisulfite pyrosequencing. B) Expression of VPS53. Mean and standard 
deviation of triplicate samples. ** = p<0.01, *** = p<0.001, **** = p<0.0001 
  
 
As 17p13.3 has been reported to be an integration site for HHV-6B (see section 1.1.3), we 
suspected this hypomethylation to be involved in HHV-6B integration. To test this hypothesis 
we used a previously developed PCR method that amplifies one of the integration sites. We 
could observe amplification of a product with anticipated size in all triplicate samples analyzed 
at 3 dpi and 6 dpi, confirming the finding by Arbuckle et al. [65] who observed HHV-6A 
integration already during lytic infection. This time frame indicates that the observed locus-
specific hypomethylation might play a role in the integration process. 
We could not observe a difference in DNA methylation in the in vivo material. This could be 
due to a transient hypomethylation. It is also likely that we did not have power to detect a 
difference due to few samples, heterogeneity within one sample (one brain biopsy contains 
many different cell types with different epigenetic landscapes) and large heterogeneity 
between individuals. Also, the percent infected cells was very low (data not shown). Taken 
together, even though the virus might induce a difference, it will probably be masked by all 
uninfected cells in the tissue or by the background noise making it hard to pick up a virus-
induced signal in a small material. If we would have used the same numbers as for the GWAS 
study in study V (n= 6808 + 5671), the results could have been different. 
This is the first study to investigate the effect of HHV-6B on DNA methylation, and these 
results open up a new dimension of the HHV-6B integration process. If I were to continue this 
project, I would first try to do a long term experiment to see if this hypomethylation is 
transient or not, answering the question if the hypomethylation is specific for the integration 
process only. Long term culture of infected cells can however be problematic as most of the 
cells will die during the lytic phase of infection. Secondly, I would investigate the TET activity, 
i.e. the de-methylating enzymes (Figure 7), during HHV-6B infection. However, a global 
change in TET levels would not explain the region-specificity observed in this study.  
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It would be very interesting to know the mechanism behind the observed site-specific 
hypomethylation. Is there a virus protein that interacts with proteins located at telomeres or 
subtelomeres? Even though the TMRs in the virus genome may explain the specificity for 17p 
[76], it does not explain the 17p-specific hypomethylation. Although there is much more to 
de done until we fully understand this process, this is a first step on the way.  
4.4 STUDY IV AND V 
Study IV and V investigate the anti-HHV-6A and/or HHV-6B IgG response in MS patients and 
controls and investigate the association between the measured antibody responses to other 
genetic and environmental factors. 
The main difference between the two studies is the antibody epitopes. The antibody 
measurement in Study IV measured all antibodies that reacted against HHV-6B lysate, while 
in study V we selected and analyzed only antibodies specific for selected protein epitopes. As 
seen in Figure 17 there is not a strong correlation between the ELISA results and the Luminex 
results. This is most likely due to that they measure different antibody specificities; The ELISA 
potentially detects all IgG antibodies specific for any virus proteins present in the HHV-6B 
virion while the Luminex assay measures antibodies specific for selected epitopes. The low 
correlation indicates that an epitope-specific response is masked in the pool of all antibodies 
against the virus.    
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Figure 17: Correlation between antibody measurements in Study IV and V. X-axes display the 
obtained OD ratios in Study IV and the y-axes show MFI values for A) IE1A, B) IE1B, C) p100 and D) 
101K obtained in Study V. X-axis for E) display “Antibody index”; an index based on sum of all 4 antigen 
divided by median value. S = Spearman correlation coefficient. Relationship also visualized with 
regression line. Note that the y-axes have different range. Data was available for 916 individuals. 
4.4.1 Association to MS 
When investigating anti-HHV-6A/6B IgG against HHV-6B lysate no difference was observed 
between MS patients and controls. However, when dissecting the antibody response we 
found, for the first time, an increased anti-IE1A and 101K IgG response in established MS 
patients compared to controls. In the opposite direction, lower IgG response against IE1B was 
associated to MS disease in women.  
In order to investigate if the difference in antibody response precedes MS onset, the HHV-6 
epitope specific antibody response was investigated in individuals who later developed MS. 
Interestingly, IE1A serostatus and levels were associated with MS risk, as were 101K IgG levels. 
A) IE1A B) IE1B 
C) p100 D) 101K 
E) Antibody index 
S = 0.10 S = 0.09 
S = 0.08 S = 0.39 
S = 0.28 
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This indicates that HHV-6A, and possibly also HHV-6B, is associated with risk of developing 
MS. In fact, the highest OR was observed for IE1A seropositivity in the youngest age group in 
the pre-MS cohort (Figure 18), indicating that the acquisition of HHV-6A might have a 
triggering effect on MS disease development. 
 
Figure 18: Seropositivity in different age groups. ORs are given for all age groups and * indicates a p-
value less than 0.05. 
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As relapsing remitting MS and progressive MS have different diseases characteristics, with the 
RRMS course being more inflammatory (see section 1.3.1), the difference in antibody levels 
between these disease courses was investigated. Unfortunately, only the disease course in 
2014 was currently available. We compared RRMS patients to primary progressive MS (PPMS) 
patients. Interestingly, as seen in Figure 19, the anti-IE1A IgG levels is higher while the anti- 
IE1B and 101K IgG levels are lower in PPMS compared to RRMS patients. Important to notice 
is that this can be due to the higher age in PPMS patients.  
 
Figure 19: Antibody levels in RRMS and PPMS patients. Log10-transformed MFI values for IgG levels 
against A) IE1A, B) IE1B and C) 101K. Median value indicated with red line. Green = RRMS (n=5052, 
median years of age=41), Purple = PPMS (n=534, median years of age=60). Cutoff values indicated with 
dotted lines. p-values calculated with Wilcoxon rank-sum test. 
4.4.2 How to interpret antibody data? 
4.4.2.1 Cutoff for serostatus and seropositivity results 
When looking at the Log10-transformed distribution of antibody levels (Figure 19), it can give 
the impression that the cutoff is set a bit arbitrary, but it is important to remember that these 
graphs do not show the original distribution. As seen in Figure 12 and 17, most of the 
untransformed MFI values are low. Another way to determine a statistical cutoff can be to 
use the median MFI among controls [96], which would yield a similar cutoff as set today 
(Figure 1 in Study V). However, the only way to determine true seropositivity is to use control 
sera with known serostatus. As we do not have a validated cutoff for determining positivity 
the exact % seropositive individuals should be interpreted with caution. However, as seen in 
Table 2, the combined seropositivities for all three epitopes measured in study V are in the 
range of 75-100% that has previously been reported as HHV-6A/6B IgG seropositivity in the 
general population [9, 11, 60-63].  
A) IE1A 
p=0.021 
B) IE1B 
p=0.0015 
C) 101K 
p=2.08x10-13 
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Table 2: Percentage seropositive in Study IV and V. # = Study IV: ELISA according to manufacturer's 
protocol. * = Study V: Luminex assay using single cutoff on the Established MS cohort. When several 
epitopes are stated (e.g. IE1B/101K) this indicates positivity for at least one of the epitopes. 
 
 
As seen in Figure 20, the IgG responses against the two HHV-6B epitopes IE1B and 101K do 
not correlate, indicating that individuals generally do not seem to have antibodies specific for 
both IE1 and 101K at the same time. This together with the data in Table 2 and the low 
correlation between anti-HHV-6A/6B IgG and the epitope-specific antibodies visualized in 
Figure 17 indicate that one protein sequence might not be sufficient for determining infection 
status in one individual.  
 
 
Figure 20: Correlation between IE1B (x) and 101K (y). One dot represents MFI values from one 
individual. Light grey = Control, dark grey = MS cases. Both the IE1B and 101K epitopes are selected 
from the HHV-6B genome.  
Epitope Virus species MS Cases Controls TOTAL
HHV-6A/6B # HHV-6A/6B 89.1 90.4 89.8
IE1A/IE1B/101K * HHV-6A/6B 83.3 79.0 81.4
IE1A * HHV-6A 53.1 43.7 48.9
IE1B/101K * HHV-6B 70.8 69.8 70.3
IE1B * HHV-6B 47.4 50.1 48.7
101K * HHV-6B 49.8 44.3 47.3
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4.4.2.2 What does an antibody response mean? 
A strong antibody response in one individual can be interpreted in different ways. It can be 
interpreted as high viral burden in this individual hence an association of serological response 
to disease would indicate that infection or recurrent reactivations with this virus is associated 
to the disease. It can also be interpreted as a good immune response with the ability to keep 
the latent infection in place, hence whenever reactivations will occur the infection is well 
controlled by the immune system in this individual. In this case, association between an 
autoimmune disease and an increased serological response would indicate that the immune 
system may induce other detrimental effects when the anti-viral response is elicited.  It is also 
likely that an antibody response can reflect both scenarios, where a high antibody level can 
reflect high viral load and a good control of the virus.   
During infection, the viral IE1 proteins are located in the host cell nucleus. As seen in Figure 
5, antibody responses are supposed to be elicited against extracellular epitopes (e.g. virus 
glycoproteins). If an antibody response is elicited against nuclear proteins, can this be a clue 
to virus pathogenesis or disease pathology? Other nuclear virus proteins give rise to similar 
responses. For example, a stronger immune response has been observed against the HHV-
6A/6B protein p41 in MS patients [170]. The p41 viral protein is located within the nucleus 
and is involved in transcription [168, 171], suggesting a similar exposure to the immune 
response as IE1A and IE1B. Also, EBNA-1 elicit a stronger immune response in MS patients 
compared to in healthy individuals [172]. Necroptosis is a form of immunogenic programmed 
cell death where cell swelling results in rupture of cell membrane and release of intracellular 
components into the surrounding tissue (reviewed in [173, 174]). Can the anti-nuclear virus 
antibodies reflect that MS patients are more prone to get virus induced cell necroptosis and 
therefore more nuclear antigens in the extracellular space? This cannot be answered in this 
setting but the hypothesis has some support in literature. First, necroptosis has been 
demonstrated to be involved in MS; markers of necroptosis were found in MS lesions and 
TNF-induced necroptosis mediates oligodendrocyte degeneration [175]. Secondly, it has 
recently been discovered that the intrathecally produced antibodies characteristic of MS 
patients often are directed against ubiquitous intracellular proteins [176], indicating tissue 
destruction in the brain. However, the increased IE1A and 101K responses in MS might be a 
consequence and not a cause of tissue destruction. In favor for a causative role, supernatant 
from HHV-6A, but not HHV-6B, infected cell cultures has been observed to induce caspase-
independent cell death (e.g. necroptosis) in oligodendrocytes in vitro [177]. 
4.4.2.3 anti-p41 IgG results 
The high p41 seropositivity (100% among HHV-6A/6B seropositive individuals) observed in 
Study IV is surprising and not in line with previously reported 28% (20/72) seropositivity 
among controls and 69% (11/16) seropositivity among MS patients [170]. Unfortunately, we 
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did not analyze any negative anti-HHV-6A/6B sera which would have given an indication of 
the assay specificity. When we bought the ELISA kit, it was newly launched on the market, 
and now it is no longer available. The result from this assay should be interpreted with 
caution.  
4.4.3 Associations to gender and age  
Females were observed to have significantly higher anti-HHV-6A/6B IgG levels compared to 
males (Study IV). This gender difference was revealed to be epitope specific and it was 
primarily anti-101K IgG levels that were increased in females and not anti-IE1A/B levels (Study 
V) nor total IgG (Study IV). If this is dependent on different virus biology in the genders or a 
difference in how females and males respond to different virus epitopes cannot be answered 
in these studies. However, female sex has been associated with increased acquisition of HHV-
6B in children [8], and it is possible that the anti-HHV-6A/6B IgG and anti-101K IgG responses 
reflect this difference in primary HHV-6B infection.  
Interestingly, the seropositivity against the HHV-6A epitope IE1A increases with age while this 
pattern was not observed for the HHV-6B epitopes IE1B and 101K (Figure 18). In fact, the 
seropositivity against 101K tend to decrease with age in the Established MS cohort. This 
indicates that HHV-6A acquisition occurs during the time period investigated while primary 
infection of HHV-6B happened earlier, probably during childhood. This difference between 
the two viruses has been suggested previously in literature [16].   
4.4.4 Genetic associations to anti-HHV-6A/6B epitope specific IgG responses  
4.4.4.1 Association to Class II HLA genes 
The absolute strongest genetic association to HHV-6A/6B IgG responses was observed 
between anti-IE1A antibody response (both serostatus and serolevels) and SNPs in the MHC 
region (Figure 21). The strongest association was found between HLA-DRB1*13:01 carriage 
and IE1A serostatus (OR 1.52, p=3x10-15). Carriage of DRB1*13:01 has previously been 
associated to stronger response against Hepatitis B vaccination [178] and this allele has been 
suggested to code for amino acids in the HLA-DRβ1 specifically important for anti-EBNA-1 IgG 
response [146]. This suggests a role for MHC class II molecules encoded by this allele in 
presentation of many viral peptides and a role in eliciting anti-viral IgG responses. Even 
though a similar manhattan plot peak at chromosome 6 has been observed for EBNA-1 
response [145, 146], the most associated SNPs previously reported for anti- EBNA-1 response 
was not associated to anti-IE1A response in our study.  
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Figure 21: Manhattan plot visualizing GWAS results for Log10-transformed IE1A IgG levels. Both MS 
and controls included in the analysis. Each dot represents the p-value of one SNP. The peak at 
chromosome 6 shows significant SNPs located in the MHC locus. Line set at p=5x10-8 indicating GWAS 
significance, and line set at 10-5 indicates suggestive association.  
 
Antibody response against IE1B and 101K did not show such strong HLA peaks as the anti-
IE1A response. One of the strongest associations for IE1B serostatus was with the HLA allele 
HLA-DRB1*07:01, however only significant in controls (OR=1.44, p=5x10-7). This allele showed 
the strongest (negative) association to EBNA-1 IgG levels in a previous study [146].  
Carriage of the MS risk allele HLA-DRB1*15:01 was not associated with a difference in anti-
HHV-6A/6B IgG levels but with higher anti-IE1A IgG levels in MS patients (β=34, p=1.1x10-12) 
and lower anti-IE1A IgG levels in controls (β=-35, p=0.01). If the association between this allele 
and increased anti-IE1A IgG response exclusively in MS cases reflects a connection between 
HHV-6A and MS cannot be answered in this setting. However, it indicates that carriage of this 
allele does not increase the anti-IE1A response per se, but that something else present in MS 
patients but not in controls, is needed for eliciting this response. 
The finding that the three different viral epitopes investigated in Study V are genetically 
associated with different HLA alleles is interesting and probably reflects differences in both 
protein sequences, function of the proteins and different species origin. The IE1A and IE1B 
protein sequences are from the same protein but coded by the different virus species, and 
the IE1B and 101K epitopes are from different proteins coded by the same virus species. Even 
though not all individuals respond to all epitopes, the polymorphism within HLA genes seems 
to ensure that most individuals respond to at least one epitope.  
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4.4.4.2 Association to Class I HLA genes 
Carriage of the MS protective HLA*A-02 allele was associated with lower levels of anti-HHV-
6A/6B IgG (Study IV). In study V, HLA*A2:01 carriage was associated with a lower anti-101K 
but higher anti-IE1A IgG response. 
B cells are activated through MHC class II (see section 1.2), so why are antibody responses 
associated to MHC class I molecules? It could be an indication of a better virus control by CD8+ 
cells. Naïve CD8+ T cells need to recognize MHC class I associated peptides together with 
costimulatory signals from an APC in order to become effector CTLs. Also, cells constantly 
present peptides from inside the cells on MHC class I molecules. It is therefore beneficial for 
an immune response against the virus if the MHC molecules of one individual are prone to 
bind and present virus-derived peptides. In line with this idea, 101K peptides are presented 
on HLA-A*02:01 encoded MHC class I molecules on HHV-6B infected cells and these infected 
cells are recognized and killed by CD8+ T cells [179]. If CTLs clear infected cells, the viral burden 
of the individual will be decreased, possibly explaining the lower levels of anti-HHV-6A/6B and 
anti-101K IgG levels in individuals with the HLA*A2:01 allele. 
In further support of an importance of MHC class I associated regulation of serological 
response to 101K, we found a genetic association between anti-101K IgG response and 3 SNPs 
in LILRB2, a gene coding for the leukocyte immunoglobulin like receptor B2 (LILRB2). This 
protein is expressed on APCs and is associated to the APC’s MHC class I molecule where it 
sterically competes with the CD8 binding [180, 181]. LILRB2 binds to different HLA-encoded 
MHC class I molecules with different binding strength and a strong binding leads to less T cell 
responses against HIV-1 [182]. Interestingly, the HLA-B*40:01 allele was associated to lower 
anti-101K IgG response (OR=0.79, β= -53), and this allele has strong binding strength to LILRB2 
[182]. The functional role of the three associated SNPs in LILR2B is not known, but the dual 
association of LILRB2 and HLA-B*40:01 with anti-101K serological response may indicate a 
role of CTL mediated clearance of virus as an important regulating factor. 
4.4.4.3 HLA association with anti-HHV-6A/6B IgG (Study IV)  
A GWAS was also done on the material in Study IV, although the results were presented 
separately (not published manuscript) and not included in Paper IV. Due to the low number 
of included subjects, this study could have been underpowered to detect genetic associations 
to anti-HHV-6A/6B IgG levels and serostatus. However, there was no peak at Chromosome 6. 
The same was true for the GWAS study by Rubicz et al. [145] where they used the same 
antibody ELISA as we did in Study IV and observed no association to SNPs at chromosome 6. 
This highlights the difference in HLA-associations observed for the different epitopes, 
suggesting that when measuring a mix of all epitope-specific antibodies, there will be no 
GWAS signal.  
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4.4.5 Future perspectives in relation to Study V 
The most important analysis to be done is to run control serum from individuals with known 
infection status so that we can conclude if the antibodies binding to the HHV-6A and HHV-6B 
specific sequences in the Luminex assay truly pick up HHV-6A and HHV-6B specific immune 
responses. Until now, we have not been able to find such samples but a collaboration has 
been initiated with Professor Yoshikawa in Japan and samples obtained from children with 
primary HHV-6B infection will be sent for analysis. If these samples do not show reactivity 
against IE1A it will at least indicate species specific detection. Also serum from macaque 
monkeys infected with HHV-6A or HHV-6B will be obtained through a collaboration with Dr. 
Jacobson in the USA. Important to remember is that a negative result can be because the 
patient/animal did not mount a response against this specific peptide. This is not unlikely as 
we show that individual tend to respond differently against different peptides. At this point 
in time, we cannot know if the peptides used actually measure species-specific responses. 
The reactivity against p100 was very low in our material and these results were interpreted 
as this peptide not working properly in the assay. As we did not have any controls to suggest 
if these results were low by nature or by an assay artefact, these results were not included in 
further analysis. However, as Higashimoto et al [55] also found a low reactivity against p100 
but strong reactivity against 101K, our p100 results might be true. Depending on the control 
results, the already measured anti-p100 IgG response may be examined more in depth until 
final conclusion can be made. 
At the moment, the presented disease courses in Study V were the disease courses they had 
in the year 2014 and not at sampling. Although many patients had the same disease course 
at sampling and in 2014, this information needs to be updated (which will take a while). And 
when correct disease courses are known, the difference between RRMS and the progressive 
forms of MS will be further investigated. 
Study IV demonstrates a difference in anti-HHV-6A/6B IgG levels between smokers and non-
smokers. Smoking data for all patients included in Study V was not available but is to be 
obtained. When this data is obtained, it would be interesting to see if smoking affects only 
some epitope-specific IgG responses or if it the decreased anti-HHV-6A/6B levels induced by 
smoking can be reflected in a general decreased antibody production. 
Since we see that HLA influences response against the different epitopes we need to rule out 
that the association we see between for example anti-IE1A IgG and MS is due to differences 
in HLA frequencies between MS patients and controls. This can be done by adding the most 
associated HLA allele for each associated haplotype to the regression models when analyzing 
association of antibodies with affection status.  
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The association between anti-viral antibody responses and MS is interesting and can give 
clues to the disease pathology, but it cannot be used for finding the mechanism behind the 
observed association. The long term aim of this project would be to investigate the role of 
HHV-6A and HHV-6B in MS disease in order to find if, and possibly how, these viruses can play 
a role in triggering or activity of the disease.   
4.4.6 Incorporation hypothesis 
If the higher anti-IE1A levels observed in pre-MS cases can be a sign of a pathologic role of 
HHV-6A in MS, what could be the mechanism? One hypothesis is the “incorporation 
hypothesis” [107]. As described in section 1.1.1.2, enveloped viruses not only contain virus 
proteins on their surface but also incorporated host cell proteins. This could mean that HHV-
6A virions released from oligodendrocytes contain myelin proteins. This could potentially 
activate both T cell responses and B cell responses (Figure 22). Dendritic cells (DCs) are key 
players in the activation of T cells; if a DC engulf a virus particle it can potentially present 
peptides derived from any of the virion proteins including the incorporated host proteins on 
their MHC class II molecules. The virus might also induce the co-stimulatory signals needed 
for DC activation of naïve autoimmune T cells. Activation of B cells does not involve DCs but 
primarily depends on activation by T helper cells. As described in section 1.2, binding of an 
antigen to the BCR will induce internalization of the BCR-antigen complex and peptides 
derived from the antigen will be presented on MHC class II molecules where they can be 
recognized by T cell receptors. Important to remember is that the BCR-specificity does not 
need to reflect what is presented on the MHC molecule, i.e. a B cell specific for a host cell 
protein can be activated by a T helper cell because of presentation of virus peptides to the T 
cell.  
According to text books, T and B cells specific against host epitopes should be deleted or 
developed into regulatory or unresponsive cells during central and peripheral tolerance 
processes (reviewed in [183, 184]). The incorporation hypothesis, and the other hypotheses 
of triggering of autoimmunity, relies on the assumption that there are immune cells with 
specificity against host proteins that have escaped these tolerance mechanisms. It has been 
implicated that immune cells with self-specificity is present in all individuals but that 
individuals with autoimmune diseases have more breaking of central and peripheral tolerance 
[184, 185]. However, even though cells can be specific for self-epitopes, they still need to get 
activated before they exert their effector function. The incorporation hypothesis also relies 
on the assumption that virus particles are released from the target cells, and that myelin 
proteins are incorporated in the virions. This needs to be clarified in the case of HHV-6A in 
oligodendrocytes.  
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Figure 22: Two hypothetic and simplified ways in which enveloped viruses induce autoimmunity. 
Activation of autoreactive A) T cells and B) B cells. DC = Dendritic cell. MBP = myelin basic protein, one 
example of host cell protein. 
 
The incorporation hypothesis explains the cell type specificity in brain and also that that 
activated immune cells find their way to the target area as there will be signs of inflammation 
making the immune cell adhere and cross endothelial barriers. In addition, at the target site 
in the brain, T cells need to be reactivated in order to attack their target and budding of viral 
particles in the area could trigger antigen presenting cells in the brain to reactivate these 
effector cells.     
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5 THESIS SUMMARY  
 
This thesis spans over several angles of HHV-6A and HHV-6B research but has three major 
focus areas: 
Assay validation: The first two studies are focused on improving quality of research. First, in 
study I we developed and compared different titer determining assays for HHV-6A. This study 
proved qPCR to be a robust readout for the TCID50 assay. In Study II, we searched for a gene 
with stable expression during HHV-6B infection to be used in gene expression analyses. This 
study proved PPIA to be stably expressed and therefore suitable to use as reference gene.  
Virus-host interaction: Study III focused on how HHV-6B affects the host cell DNA methylation. 
We could, for the first time, show that HHV-6B induces hypomethylation close to the 
telomeres and that this process most likely plays a role in virus integration into the host cell 
genome. In study V, the association between HLA alleles and the IgG response against HHV-6 
specific epitopes was investigated. This study revealed that the host HLA genotype plays an 
important role in shaping the specificity of the elicited anti-HHV-6A/6B antibody response.  
Clinical relevance: In study III, we investigated the role of HHV-6B on DNA methylation in 
epileptic tissue, with the aim of finding a pathogenic role of this virus in epilepsy. 
Unfortunately, no firm conclusion can be drawn from this investigation due to low power of 
the analysis. More successfully, we investigated antibodies against HHV-6A and HHV-6B in 
multiple sclerosis patients and controls in study V. We could, for the first time, show that anti-
IE1A and anti-101K IgG responses are increased in MS patients and these responses may 
indicate a role of these viruses in MS pathology.  
To conclude, we have found that HHV-6B affects the host cell epigenetic landscape possibly 
leading to health consequences. However, proving a link between ubiquitous viruses like 
HHV-6A and HHV-6B and diseases is hard as several factors are involved. To be infected is not 
enough to cause diseases like MS and epilepsy, and what influences the virus-host interaction 
is therefore of interest. Even though these viruses have been associated to different diseases, 
finding the mechanisms behind the reported associations are desirable and the only way to 
understand what the associations reflect. Finding pathogenic mechanisms can ultimately lead 
to better diagnostics and new much more specific treatment options.  
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